ZEVEX INTERNATIONAL INC
BUSINESS     OVERVIEW   ZEVEX( International, Inc. (“ZEVEX”) through our two divisions, engages in the business of designing, manufacturing, and distributing medical devices.  Our Therapeutics division designs, manufactures and markets enteral nutrition pumps, disposable sets and accessories.  Our Applied Technology division designs and manufactures advanced medical components and systems for other medical technology companies.  Until its sale on December 31, 2003, our Physical Evaluation division marketed physical evaluation testing systems.     We develop and manufacture high quality, high value medical products.  We effectively integrate, implement, and support solutions throughout product life cycles based upon our core competencies in sensing, fluid management, and surgical ultrasound technologies.  We provide value in a continuum of product solutions, as a diversified medical device company committed to creating products that transform life with patented and proprietary medical device technologies – from sensors and surgical tools to medical electronic systems.   We focus on product development and manufacturing, and distribute our products through selected medical device marketing companies and distributors.  We employ product and territory managers to ensure that our services and sales support are complementary to the quality of our innovative products.  This distribution strategy allows us to leverage our expertise and technology across diverse applications, while remaining focused on our core competencies.   In 2003, we began restructuring our operations to focus on our core market offerings of our ambulatory enteral feeding products (our Therapeutics division) and contract manufacturing services (our Applied Technology division).  As part of our efforts to refocus on our core business during 2004, we executed several strategic agreements with Royal Numico N.V., a Netherlands corporation, which is a world leader in the manufacturing and marketing of clinical nutrition products, related equipment and accessories (see Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations).   During the first quarter of 2005, we completed a research and development project leading to the introduction of our next-generation enteral feeding pump, the EnteraLite® Infinity®, at the American Society of Parenteral and Enteral Nutrition Annual Conference in January 2005.  The EnteraLite® Infinity® provides patients in hospitals, nursing homes, or at home with the lightest, most accurate, and longest lasting, battery-operated pump available.    In June 2005, we received a 2005 Silver Medical Design Excellence Award for the EnteraLite® Infinity® at the Medical Design & Manufacturing East trade show in New York City.  We also developed and manufacture a custom optoelectronic sensor for a product of Baxter Healthcare that received a 2005 Gold Medical Design Excellence Award at the same trade show.     In August 2005, Nutricia Clinical, the clinical nutrition division of Royal Numico, announced the European launch of the Flocare® Infinity® enteral pump.  Nutricia Clinical is our exclusive distributor for a private-label version of our EnteraLite® Infinity® enteral feeding pump.   In 2005, our consolidated revenue grew 28%, to $30,273,922 and we produced record net income of $1,905,378.  We had consolidated revenue of $23,634,355 and a net loss of $178,977 in 2004, and consolidated revenue of $25,869,876 and a net loss of $8,277,542 in 2003.  Revenue from our Therapeutics and Applied Technology divisions constituted 56% and 44%, respectively, of our 2005 consolidated revenue, 53% and 47%, respectively, of our 2004 consolidated revenue and 48% and 40%, respectively, of         our 2003 consolidated revenue.  In 2003, our Physical Evaluation division, which has since been divested, produced 12% of our consolidated revenue.     In 2005, our Applied Technology division experienced sales growth of our core sensors and surgical ultrasound products.   Our largest customers for these products posted market share gains, from which we benefited.  As a result, the Applied Technology division produced revenue of $13.4 million in 2005, achieving growth of 20% over 2004.   In 2005, our Therapeutics division produced revenue of $16.9 million, achieving growth of 35% over 2004.  Based upon the introduction of the EnteraLite® Infinity® product line and the continued sales strength of our original EnteraLite® product line, our domestic Therapeutics sales force produced revenue of $11.8 million, achieving growth of 11% over 2004.   However, the most significant growth in our Therapeutics division in 2005 came from the global expansion of sales of our Therapeutics product line through Nutricia Clinical.  As we forecasted at the end of 2004, we generated more than $3.5 million in new sales to Nutricia Clinical during the launch of the Flocare® Infinity® in Europe in the second half of 2005, driving total international Therapeutics revenue to a record of more than $5 million for the year.     Last year, we increased our selling and marketing expenses, hiring a vice president of sales and marketing and a director of business development in Europe.  We also continued to invest in research and development in both our Therapeutics and Applied Technology businesses in order to bring new products to market.  Due to our sales growth in 2005 and cost management, our selling, general and administrative expenses actually decreased as a percentage of sales, from 30% in 2004 to 27% in 2005.  Research and development expenses decreased in 2005, as we completed the development of our Infinity product line early in the year.   We continued to reduce our funded debt in 2005, which has decreased by approximately $13 million or 87%, since January 2001.  During this period we also redefined our operating segments, implemented lean manufacturing, and focused on our core competencies.  Our operations are now based upon common or related technologies, enhancing the development and manufacturing of innovative products, improving product quality and our service performance, and providing for efficient sharing of business resources.   Therapeutics Division   Through the sale of enteral feeding pumps and related devices, our Therapeutics division has established a competitive position in the U.S. and increasingly, the European enteral nutrition delivery markets.  The market in which we compete includes feeding pumps and disposable sets that are used by patients who require direct gastrointestinal nutrition therapy (also called enteral feeding).  Enteral feeding is the means of providing liquid nutrition to patients who may have experienced head or neck trauma, or have gastrointestinal disorders, such as short bowel syndrome, Crohn’s Disease, bowel pseudo-obstruction or other disorders that prevent normal digestion.   Applied Technology Division   Our Applied Technology division provides design and manufacturing services in a multi-billion dollar market to worldwide medical device leaders who, in turn, sell our components and systems under private labels or incorporate them into their products.    These OEM (Original Equipment Manufacturer) products include ultrasonic sensors and surgical handpieces, optoelectronic components, and electronic instruments.  Our operation in Salt Lake City has been certified to world-class medical device quality standards, meeting ISO 9001:2000 and ISO 13485:2003 certification requirements, and we employ a quality system developed to meet the U. S. Food and Drug Administration’s Good Manufacturing Practices.                The Sale of Our Physical Evaluation Division   Until December 31, 2003, we competed in the Physical Evaluation market through our sales of stand-alone and computerized products that measure isolated muscle strength, joint ranges of motion and sensation.  We called this our Physical Evaluation division.  On December 31, 2003, we completed the sale of our Physical Evaluation business.  The transaction was accomplished by the sale of all the issued and outstanding capital stock of JTech Medical Industries, Inc., (“JTech”), our wholly-owned subsidiary.  The transaction was effected by a Stock Purchase Agreement (the “Stock Purchase Agreement”) dated December 31, 2003 by and between ZEVEX and Mr. Leonard C. Smith, a former employee, officer and director of ZEVEX.  (See Item 7. Management Discussion and Analysis of Financial Condition and Results of Operations).  We sold the Physical Evaluation division in an effort to focus on our core competencies.   Financial Information   For information regarding our financial condition and results of operations see Item 8 of the report entitled “Financial Statements and Supplementary Data” and Notes to Consolidated Financial Statements included in that item.  See also the discussion of the financial performance of our segments in Note 12 to the Consolidated Financial Statements.   Contact and Additional Information   We maintain our executive offices and principal facility at 4314 ZEVEX Park Lane, Salt Lake City, Utah 84123.  Our telephone number is (801) 264-1001.  We maintain an Internet site at http://www.zevex.com.  We make available free of charge through this website our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 as soon as reasonably practicable after we electronically file such material to the Securities and Exchange Commission.  Our website and the information contained therein or connected thereto shall not be deemed to be incorporated into this Form 10-K.   PRODUCTS AND TECHNOLOGY   We develop and manufacture high-quality, high-value medical products based upon our core competencies in sensing, fluid management, and surgical ultrasound technologies.  These products are distributed under our own label as well as private labeling for many major medical device companies.   Domestically, products with our label are distributed via a national sales force that works with home health care companies, medical device marketing companies, and distributors across the United States to provide patients with the best quality products possible.  Internationally, we partner with large food companies such as Royal Numico and Nestlé, who distribute our products in over 32 countries.   This distribution strategy allows us to leverage our expertise and technology across diverse applications such as pumps and disposables for enteral feeding; ultrasonic and optoelectronic sensors; ultrasonic handpieces; and drive circuits and interface systems for a variety of medical applications   OUR PROPRIETARY PRODUCTS          Therapeutic Products     Through our Therapeutics division, we sell two major lines of enteral feeding pumps and a variety of related disposable delivery sets and accessories.  Enteral feeding is a method of delivering nutrition to patients through the gastrointestinal tract.  Many enteral feeding patients require continuous administration of nutritional solutions throughout the day, which requires the patient to carry an enteral feeding pump.     We have successfully applied our engineering and regulatory expertise to the development,         commercialization, and marketing of our next generation enteral feeding pump, the EnteraLite® Infinity®, for patients who require direct gastrointestinal nutritional therapy.  We believe that the EnteraLite( Infinity® pump is the lightest, most compact, most durable, and most mobile enteral feeding pump in the global market, possessing unprecedented safety, accuracy and durability in enteral nutrition delivery.  Like its predecessor the EnteraLite(, the EnteraLite® Infinity®, has unique features which include the ability to operate in any orientation, +/-5% accuracy and a 24-hour battery, which is one-third longer than the battery life of its closest competitor.   The EnteraLite® Infinity® builds upon the proven user interface and superior accuracy of the original EnteraLite® pump, with an expanded feature set that provides benefits of use in a wide variety of enteral feeding applications.  The unique features of the EnteraLite® Infinity® are the result of input from patients, clinicians, caregivers and durable medical equipment providers.  The accuracy, portability, size, and ruggedness of the EnteraLite® Infinity® allow patients to remove the traditional barriers of utilizing an enteral feeding pump.  In the U.S. today, the most commonly used enteral feeding pumps are mounted on an I.V. pole and the patient is tethered to the pole throughout the feeding, which can take a number of hours.  For patients who need to feed during the day, the I.V. pole limits their ability to be physically active.  We believe that the EnteraLite® Infinity® may provide access to new customers and applications that were previously beyond our reach.   First introduced in 1996, the original EnteraLite( product line gained acceptance in the home health care market due to its superior mobility and state-of-the-art features.  We believe that by improving the convenience of nutrition delivery, the EnteraLite(  and EnteraLite® Infinity® can contribute to better clinical outcomes and improved quality of life for enteral patients.  The EnteraLite( and EnteraLite® Infinity® require the use of disposable feeding bags and tubing sets, which are also sold by us.  ZEVEX has been awarded thirty-five U.S. patents for technology related to the EnteraLite( Infinity® and EnteraLite( and associated disposable sets.    We expanded our line of enteral delivery products with the 1998 acquisition of Nutrition Medical’s line of stationary pumps and delivery sets, and the 2000 acquisition of the installed base of Nestlé USA stationary pumps.  We continue to manufacture and distribute these lower cost stationary enteral feeding pumps that are intended for applications where patients are not mobile.  Complementing these pump models are a line of disposable delivery sets sold by us for use with the pumps.  These sets include feeding solution bags of various sizes, as well as “spike” sets for use with pre-filled feeding solution containers.   APPLIED TECHNOLOGY DESIGN AND MANUFACTURING SERVICES   Though our Applied Technology division we provide design and manufacturing services to medical companies who sell our components and systems under private labels or incorporate them into their products.  We provide these services for both established and emerging technology companies, such as Cardinal Health, Inc. (formerly Alaris Medical Systems, Inc.,), Advanced Medical Optics, Inc., Baxter Healthcare Corporation, Medtronic Corporation, Smith’s Industries, Inc., Edwards Lifesciences and Terumo Corporation.  We offer our customers over 19 years of specialized engineering and manufacturing expertise.   Industry sources indicate a continued trend by medical device companies to outsource their device manufacturing requirements.  Many emerging companies do not have the engineering, manufacturing, or regulatory expertise to quickly and efficiently take a device from conception to commercial use.  Even larger, well-established companies, which may have the capital to develop such expertise, may lack the required personnel and time to accumulate such expertise or may want to focus their resources in areas other than manufacturing.  In the medical device industry in particular, there are substantial regulatory compliance requirements, in both the United States and overseas, that must be addressed in both designing and manufacturing such devices.  By focusing our resources and expertise in the design and manufacturing areas, we believe that we offer customers the ability to outsource engineering and manufacturing needs on a cost-effective basis, often allowing the customer to take a product to market more quickly and efficiently, at a lower cost, and with higher quality than a customer could achieve with its own resources.  We use extensive engineering and regulatory expertise to deliver integrated design and manufacturing         solutions to our customers.  We are registered with the United States Food and Drug Administration (“FDA”) as a medical device manufacturer and have developed internal systems intended to maintain compliance with the FDA’s Good Manufacturing Practices (“GMP”).  We also are certified by the International Organization for Standardization (“ISO”) to 9001:2000 and ISO 13485:2003 standards, which means that we have met internationally recognized quality standards for the design, manufacture, and testing of products.  We devote significant management time and financial resources to GMP compliance and ISO certification.    PRINCIPAL OEM PRODUCTS    Most of our Applied Technology division business involves the following four general product categories:          Ultrasonic Surgical Handpieces       We design and manufacture ultrasonic phacoemulsification handpieces and handpiece drive circuits for the surgical removal of cataracts.  Phacoemulsification is a method of cataract extraction that uses ultrasound waves to break the cataract-obstructed lens of the eye into small fragments that can be removed through a hollow needle.  Phacoemulsification is currently used in more than 90 percent of cataract procedures in the United States.            Ultrasonic Sensors     We design and manufacture a variety of non-invasive ultrasonic sensors for the detection of air bubbles and the monitoring of liquid levels in critical medical systems.  Our air bubble detectors monitor intravenous fluid lines in drug infusion pumps, hemodialysis machines, blood collection systems, and cardiopulmonary bypass systems.  Our liquid level detectors utilize ZEVEX’s patented dry acoustic coupling technology and are used to monitor critical liquid levels in reservoirs employed in cardiopulmonary bypass systems.           Optoelectronic Sensors       We design and manufacture a variety of optical emitters and detectors used in medical applications.  Our product capabilities include custom emitter and detector arrays, sensor interface circuits and custom device packaging.  Medical applications for our products include diagnostic and therapeutic equipment, such as blood analyzers and dialysis machines.           Medical Systems     The highest kind of integration for our contract services involves the design, engineering, and manufacturing of medical systems.  During 2005, we provided design and engineering services to Organ Recovery Systems, Inc. and performed on manufacturing contracts to supply LifePort™ hypothermic perfusion transporters and disposable perfusion sets for kidneys.  We also manufactured the Power Medical Interventions, SurgASSIST™, which is a computer-mediated technology platform that provides a unique level of intraluminal access, surgical precision, and patient safety, with applications in numerous surgical stapling procedures throughout the alimentary tract.                      REVENUE SOURCES   The following table sets forth the sources of ZEVEX’s total revenue during the last three years, allocated between six product/service categories.   Revenue breakdown by product/service, by percentage      Product   2005   2004   2003     Therapeutics   55.8%   52.8%   48.0%     Ultrasonic and Optoelectronic Sensors   22.0%   19.7%   19.8%     Ultrasonic Surgical Devices   12.3%   14.2%   11.0%     Medical Systems   8.5%   11.7%   2.3%     Design and Engineering Services   1.4%   1.6%   7.2%     Physical Evaluation*   0.0%   0.0%   11.7%   * On December 31, 2003 we sold our Physical Evaluation business.   CAPABILITIES FOR DESIGN, ENGINEERING AND MANUFACTURING          Design and Engineering     We have extensive design and engineering capabilities that we use for our own product development, as well as for servicing our contract-manufacturing customers.  Our engineers have broad experience in designing, engineering, and testing an array of medical devices and systems, with particular expertise in sensors, fluid management, and surgical ultrasound.    Our manufacturing service customers generally rely on us from the outset of their projects for complete design, engineering, component analysis, testing, and regulatory compliance for their devices or systems.  In some instances, customers have come to us with final drawings for products that they believe are ready for manufacturing.  Our engineers assist sales and marketing personnel in evaluating requests for proposals and in developing proposed solutions, cost estimates, and bids for each product.  Our design and engineering services are generally provided to customers on a time-and-materials fee basis, as part of a plan to eventually manufacture the customer’s product.   We have made significant investments in state-of-the-art equipment to support our design and engineering staff, including product performance modeling software, custom test stations, and three-dimensional computer aided design (“CAD”) software.  We have independently developed what we believe is the most sophisticated modeling software for ultrasonic surgical device development.  We believe that our unique modeling and design capacities hasten product development and improve the quality of the final device.            Manufacturing     Our proprietary products are generally assembled and tested at our manufacturing facility in Salt Lake City, Utah.  Design, engineering, and manufacturing services for other companies are also provided from our Salt Lake City facility.  Our disposable products are sub-contracted to specialty manufacturers.     Software inventory management systems are used to manage inventory and control the ordering process for more than 5,000 parts used in ZEVEX’s and our customers’ products.  As the evolution of a device or system reaches production, team members with direct responsibility for purchasing, manufacturing, and quality assurance assume a greater role in the project.  The project team develops an assembly process, product testing protocol, and quality assurance procedures to produce high-quality products that satisfy internal and external specifications, as well as the FDA’s GMP and ISO 9001:2000/ISO 13485:2003 quality standards.               We usually provide design and engineering services pursuant to negotiated manufacturing agreements, which address quantity, pricing, warranty, indemnity, and other terms of the relationship.  Such contracts may or may not be exclusive manufacturing arrangements, and may or may not include minimum volume requirements.  In some cases, no minimum purchase is required.  In other cases, a customer commits to purchase a minimum quantity identified in a rolling forecast of production.  We warrant our products to be free from defects in materials and workmanship for periods ranging from 90 days to the life of the product.    SUPPLIERS   We purchase our component parts and raw materials from a variety of approved suppliers.  We are not dependent on a single supplier for any item, and we believe that we can acquire materials from various sources in adequate quantities and on a timely basis.    SALES AND MARKETING   Therapeutic Products   We have a network of direct territory managers who sell enteral pumps and disposable delivery sets in the United States.  These territory managers have been selected for their experience within the markets in which we sell our products, and they sell directly to home health care service providers, hospitals, nursing homes and medical product distributors.  The direct territory managers are regionally supported by specialists with clinical credentials (registered dietitians or nurses), who we hire on an independent contractor basis.  We employ a North American sales manager to manage and deploy our sales resources effectively in these major markets.   In the United States, customers generally purchase EnteraLite® and EnteraLite® Infinity® ambulatory enteral feeding pumps directly from us.  In cases where a lease or rental is preferred, arrangements are most often made through a third party that specializes in medical equipment financing.  Customers then purchase disposable sets as needed.  Customers typically purchase 10 - 15 disposable sets per month for each pump that is placed in service.   Due to competition, lower-cost stationary pumps generally have been placed at no up-front cost to the user, in return for set “usage” agreements, which typically require minimum purchases of 15 disposable sets per pump per month, once the pumps are placed in service.  The cost of the pump is then amortized.   In North America, the distribution of the EnteraLite® and EnteraLite® Infinity® ambulatory pump, stationary pumps, and delivery sets are serviced by our sales support manager, inside sales specialists, and customer service department, in addition to the outside sales force described above.     Nestlé is our distributor for the EnteraLite® in Germany where it also distributes its clinical nutrition products.  Medicina distributes the EnteraLite® in the United Kingdom, and Baxter Healthcare distributes our entire enteral feeding product line in Puerto Rico.  During 2005, a version of our stationary pump was manufactured under private label for distribution by Nestlé in Europe.    In August 2005, the clinical nutrition division of Royal Numico, Nutricia Clinical announced the European launch of the Flocare® Infinity® enteral pump.  Nutricia Clinical is our exclusive distributor for a private-label version of our EnteraLite® Infinity® enteral feeding pump in over thirty countries, including parts of Africa, Asia, Australia, Europe, the Pacific Rim, and South America.     Applied Technology Design and Manufacturing Services     We generate new design and manufacturing projects using direct sales personnel who are trained in our engineering expertise and manufacturing capabilities.  Project engineers also participate extensively in sales and marketing activities.  We promote our design and manufacturing capabilities at industry trade shows, by advertising in leading industry publications, through our website www.zevex.com, and by obtaining referrals from customers and other persons who are familiar with our services.              COMPETITION   Therapeutic Products   We have three major competitors in the U.S. market for enteral feeding pumps.  Ross Laboratories, a division of Abbott Laboratories, markets the Patrol( and Quantum( stationary enteral feeding pumps, and the Companion( and Embrace( ambulatory enteral feeding pumps.  Frost & Sullivan marketing research estimates that Ross holds approximately 46% market share for enteral pumps and delivery sets in both ambulatory and non-ambulatory enteral feeding applications.  Kendall Healthcare, a division of Tyco, offers the kangaroo( PET enteral feeding pump for ambulatory applications, which has limited application because it can be operated only in an upright position.  Kendall also markets its new E-pump(, Control( and Entriflush( pumps for stationary applications.  Frost & Sullivan marketing research estimates that Kendall Healthcare presently holds approximately 25% of the total market for enteral pumps and disposable sets in both ambulatory and non-ambulatory applications.  In addition to Ross Laboratories and Kendall Healthcare, a third competitor, Novartis also competes in the U.S. market for stationary enteral nutrition delivery pumps.  Frost & Sullivan marketing research estimates that Novartis presently holds approximately 14% of the total U.S. market for enteral pumps and disposable sets in both ambulatory and non-ambulatory applications.     Well-established competitors such as Ross Laboratories, Kendall Healthcare, and Novartis typically bundle products for the greatest advantage in group-purchasing situations.  Each of these competitors offers a range of product offerings that exceeds that of ZEVEX.  We believe the keys to our ability to compete effectively in the enteral feeding market are the unique features of our product offerings and the benefits to customers who utilize them.  We expect to build upon our reputation for innovation that was earned by our EnteraLite( ambulatory enteral feeding pump for mobile enteral patients with the EnteraLite® Infinity® and believe that it may provide access to new customers and applications that were previously beyond our reach.  We expect to develop products that are complementary to our enteral nutrition delivery product line, particularly those having features that can significantly improve a patient’s quality of life and can ensure safety and ease of enteral administration.           Applied Technology Design and Manufacturing Services       The largest competitors for design and manufacturing services include Benchmark Electronics, Nova Biomedical, Plexus, Inc., Sanmina-SCI Corp., and Sparton Electronics Corporation.  These contract manufacturers operate in the medical technology industry, and some have substantially greater financial and marketing resources than we do.  Competitive factors in medical device design and manufacturing include technology strengths, quality, regulatory compliance, engineering competence, cost of non-recurring engineering, price of the manufactured product, experience, customer service, and the ability to meet design and production schedules.  We believe that our unique expertise in sensing, fluid management, and surgical ultrasound will allow us to compete effectively for contracts involving these technologies.   PATENTS AND TRADEMARKS   As of December 31, 2005, we held thirty-five U.S. patents and thirty international patents on devices developed by us, with additional U.S. and international patents pending.  The loss of certain patents that are key to our proprietary products could have a materially adverse effect on our overall business operations.  We also rely on trade secrets and confidentiality agreements to protect the proprietary nature of our technologies.    In addition, we own and have applied for numerous trademarks in the United States and abroad.  We believe that our trademarks are well recognized in the various markets for our products.  With the exception of the Infinity®, EnteraLite® and LifeGuard® trademarks, which are registered for our enteral feeding products, we believe that the loss of any trademark would not have a material adverse effect on our overall business operations.            RESEARCH AND DEVELOPMENT FOR OUR PROPRIETARY PRODUCTS AND TECHNOLOGY   In addition to the research and development that we conduct on a contract basis, we also devote substantial resources to our internal research and development projects to enhance our Therapeutics technologies and our core technologies in the Applied Technology business.  Our research and development efforts are primarily focused in three areas: (1) developing enhancements to our existing technology and proprietary knowledge; (2) developing new proprietary processes and intellectual property to serve new and existing customers within our current business segments; and (3) researching new applications to service the needs of new customers in those segments.  As of December 31, 2005, we have seventeen full-time engineers in research and development, and have several other designers and engineers, including independent contractors, contributing to research and development projects.  Our research and development staff performs engineering research and development services for both internal product development and  for customers of our Applied Technology division on a fee for service basis.  We invested $1,208,466 in 2005, $1,430,692 in 2004, and $1,817,581 in 2003 for internal research and development of new products.  In 2005, research and development costs represented approximately 4% of our annual revenue, compared to 6% in 2004 and 7% in 2003.  During 2003, approximately $763,000 was related to research and development costs for our Physical Evaluation business, which was sold in December 2003.     MAJOR CUSTOMERS   Historically, large portions of our revenue were not attributable to a single customer. However, during 2005 Cardinal Health, a customer for ultrasonic sensors accounted for approximately 14% of revenue and Numico, the exclusive distributor of certain ZEVEX enteral feeding pumps in over thirty countries, accounted for approximately 13% of revenue.  During 2004, McKesson HBOC, a distributor of products in our Therapeutics Division, accounted for approximately 11% of revenue.  During 2003 no single customer accounted for over 10% of revenue.  If any customer with whom we do a substantial amount of business were to encounter financial distress, the customer’s lateness, unwillingness, or inability to pay its obligations to us could have a material adverse effect on our results of operations and financial position.   BACKLOG   At December 31, 2005, we had a backlog of approximately $8,143,000 on orders for medical devices to be manufactured for other medical technology companies, as compared to a backlog at December 31, 2004 and 2003, of approximately $5,365,000 and $4,861,000, respectively.  We estimate that approximately 90% of this backlog will be shipped before December 31, 2006.  As of March 13, 2006, we had a backlog of $9,292,772.  For purposes of the above figures, backlog includes product not yet shipped pursuant to purchase orders that have been received by us.  This does not include any backlog for our Therapeutics division proprietary products, because we generally hold appropriate levels in inventory for sale to customers.  Some of the orders included in the backlog may be canceled or modified by customers without significant penalty.  In addition, because customers may place orders for delivery at various times throughout the year, and because customers may change delivery schedules or cancel orders, our backlog as of any particular date may not necessarily be a reliable indicator of future revenue.   GOVERNMENTAL REGULATION   Our manufacturing facility, customers’ medical devices, and our proprietary medical devices are subject to extensive regulation by the FDA under the Food Drug and Cosmetics Act (“FDC Act”).  Manufacturers of medical devices must comply with applicable provisions of the FDC Act and associated regulations governing the development, testing, manufacturing, labeling, marketing, and distribution of medical devices, as well as record-keeping requirements, and the reporting of certain information regarding device safety.  In addition, our facility is subject to periodic inspection by the FDA for compliance with the FDA’s GMP requirements.  To ensure compliance with GMP requirements, we expend significant time, resources, and effort in the areas of training, production, and quality assurance.             For certain medical devices manufactured by us, the customer may need to obtain FDA clearance in the form of a premarket approval (“PMA”) application.  Such applications require substantial pre-clinical and clinical testing to obtain FDA clearance.  Other medical devices can be marketed without a PMA, but only by establishing, in a 510(k) premarket notification, “substantial equivalence” to a predicate device.    Besides the FDA regulations described above, we are also subject to various state and federal regulations with respect to such matters as safe working conditions, manufacturing practices, fire hazard control, environmental protection, and the disposal of hazardous or potentially hazardous materials.  Our operations involve the use and disposal of relatively small amounts of hazardous materials.   Beginning in 1998, all medical device manufacturers were required to obtain the “CE Mark” to sell their products in the European Common Market.  The CE Mark is a quality designation given to products that meet certain policy directives of the European Economic Area.  We have received and maintain ISO 9001:2000 and ISO 13845:2003 certification, which allows us to CE Mark our own products and assist our customers with obtaining the CE Mark for their products.    As part of a nationwide investigation into billing practices associated with enteral nutrition delivery products, particularly in regard to billing practices for pumps and disposable delivery sets, on July 2, 2001, the U.S. Office of Inspector General (OIG), served a subpoena on the ZEVEX, Inc. subsidiary.  According to published reports, the investigation involved most manufacturers, distributors and health care service providers in the United States enteral pump industry and similar subpoenas were served on many of those parties.  The subpoena requested documents relating to our enteral pump customers’ marketing and billing practices.  We responded to the subpoena.  Since October of 2001 we have not been contacted further by the OIG, although we understand the investigation is proceeding and we intend to cooperate with the investigation if contacted again.  At this time we are uncertain as to any future impact this investigation will have on our operations or financial position.   EMPLOYEES   As of March 13, 2006, we employed a total of 158 people in the following areas: 101 in Manufacturing, Testing, and Quality Assurance; 18 in Design and Engineering; 18 in Administration; and 21 in Sales and Marketing.  We have 131 employees located at our corporate headquarters and manufacturing facility in Salt Lake City, Utah, 8 employees at various other locations throughout the United States and one employee in Europe.   We consider our labor relations to be good, and none of our employees are covered by a collective bargaining agreement.  Currently, the local economy is stable and the unemployment rate is moderate in the Salt Lake City metropolitan area, which means that we face competition to attract and retain qualified personnel.  However, at the same time, the Salt Lake City metropolitan area has a well-educated work force and is considered an attractive place to live.  Accordingly, we do not anticipate having difficulty in attracting and retaining qualified personnel to meet our projected growth, although we believe that labor costs will likely increase moderately.   ENVIRONMENTAL COMPLIANCE COSTS   We believe that we are in compliance with all applicable environmental regulations.  We believe that our efforts to comply with federal, state, and local provisions regarding the production and discharge of material into the environment and the protection of the environment will not have a materially adverse effect on our capital expenditures, earnings and our competitive position.    FINANCIAL INFORMATION ABOUT FOREIGN AND DOMESTIC OPERATIONS AND SALES   During the 2005 fiscal year, we generated total revenue of $30,273,922, of which $6,805,033 (22%) was considered foreign source revenue.  During the 2004 fiscal year, we had total revenue of $23,634,355, of which $3,168,587 (13%) was considered foreign source revenue.  During the 2003 fiscal year, we had total revenue of $25,869,876, of which $4,380,461 (17%) was considered foreign source revenue.              During the last three fiscal years, we have had no long-lived assets, long-term relationships with a financial institution, mortgage or other servicing rights, deferred policy acquisition costs, or deferred assets, in any foreign country.   ORGANIZATIONAL STRUCTURE   ZEVEX is a Delaware corporation organized in 1986.  It serves primarily as a holding company, conducting business operations through our wholly-owned subsidiary ZEVEX, Inc., a Delaware corporation.  Until December 31, 2003 we also conducted business through a wholly-owned subsidiary JTech Medical Industries, Inc., a Utah corporation, which marketed our Physical Evaluation product line.   On December 31, 2003, we completed the sale of the Physical Evaluation business.  The transaction was accomplished by sale of all the issued and outstanding capital stock of JTech.  The transaction was effected by a Stock Purchase Agreement (the “Stock Purchase Agreement”) dated December 31, 2003 by and between us and Mr. Leonard C. Smith, a former employee, officer and director of ZEVEX.  (See Item 7 Management’s Discussion and Analysis of Financial Condition and Results of Operations)      ITEM IA.   RISK FACTORS     The disclosure and analysis set forth in this 2005 Form 10-K contain certain forward-looking statements, particularly statements relating to future actions, performance or results of current and anticipated products, sales efforts, expenditures, and future financial results.  From time to time, we also provide forward-looking statements in other publicly-released materials, both written and oral.  These statements are statements that do not relate strictly to historical or current facts.  When used in this report or our other publicly-released materials, the words such as “plans,” “expects,” “will,” “estimates,” “believes,” “projects,”  “anticipates” and similar expressions, together with other discussion of future trends or results, are intended to identify forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended.  In all cases, a broad variety of risks and uncertainties, known and unknown, as well as inaccurate assumptions can affect the realization of the expectations or forecasts in those statements.  Consequently, while such statements represent our current views, no forward-looking statement can be guaranteed.  Actual future results may vary materially.   We undertake no obligation to update any forward-looking statements, but investors are advised to consult any further disclosures by us in our subsequent filings pursuant to the Securities Exchange Act of 1934, as amended.  Furthermore, in accordance with the Private Securities Litigation Reform Act of 1995, we provide the following cautionary statements, identifying factors that could cause our actual results to differ materially from expected and historical results.  It is not possible to foresee or identify all such factors.  Consequently, this list should not be considered an exhaustive statement of all potential risks, uncertainties, and inaccurate assumptions.    Additionally, the following factors should be reviewed for a full understanding of our business and considered in evaluating our prospects for future growth.  The occurrence of one or more of the following risks or uncertainties could have a material adverse effect on our business, results of operations, and financial condition.   RISK FACTORS IN MARKETING OUR PROPRIETARY PRODUCTS   With respect to our proprietary products, we face numerous technology, regulatory, financial, management and other operational risks, including the following:   Large, Well-Funded Competitors   The medical products industry is highly competitive.  A significant number of our competitors have substantially greater capital resources, research and development staffs, facilities, and substantially greater experience in developing new products, obtaining regulatory approvals, and manufacturing and marketing         medical products.  Competitors may succeed in marketing products preferable to our products or rendering our products obsolete.   Changes in Technology   The medical products industry is subject to significant technological change and requires ongoing investment to keep pace with technological development, quality, and regulatory requirements.  In order to compete in this marketplace, we will be required to make ongoing investment in research and development with respect to our existing and future products.   Regulatory Oversight   We are subject to substantial risks involved in developing and marketing medical products that are regulated by the FDA and foreign agencies.  There can be no assurance that we will obtain the necessary FDA or foreign clearances on a timely basis, if at all.  As discussed above, commercialized medical products are subject to further regulatory restrictions, which may adversely affect us.  Changes in existing laws and regulations or policies could adversely affect our ability to comply with regulatory requirements.    Regulatory Compliance for Manufacturing Facilities   We expend significant time, resources, and effort in the areas of training, production, and quality assurance to maintain compliance with applicable regulatory requirements.  There can be no assurance, however, that our manufacturing operations will be found to comply with GMP regulations, ISO standards, or other applicable legal requirements or that we will not be required to incur substantial costs to maintain our compliance with existing or future manufacturing regulations, standards, or other requirements.  Our failure to comply with GMP regulations or other applicable legal requirements can lead to warning letters, seizure of non-compliant products, injunctive actions brought by the U.S. government, and potential civil or criminal liability on the part of ZEVEX and officers and employees who are responsible for the activities that lead to any violation.  In addition, the continued sale of any instruments manufactured by us may be halted or otherwise restricted.   Market Acceptance   There can be no assurance that our products will gain any significant market acceptance in their intended target markets, even if required regulatory approvals are obtained.   Government Reimbursement   Revenues for many of the medical devices manufactured by us may be dependent in part on availability of adequate reimbursement for those devices from third-party health care payers, such as government and private insurance plans.  There is no assurance that the levels of reimbursements offered by third-party payers will be sufficient to achieve market acceptance of our products.   Product Development   Our success will depend to a significant extent upon our ability to enhance and expand our current offering of proprietary products and to develop and introduce additional innovative products that gain market acceptance.  While we maintain research and development programs and have established various technical advisory boards to assist us, there is no assurance that we will be successful in selecting, developing, manufacturing, and marketing new products or enhancing our existing products on a timely or cost-effective basis.  Moreover, we may encounter technical problems in connection with our efforts to develop or introduce new products or product enhancements.  Some of the devices currently being developed by us (as well as devices of some of our customers) will require significant additional development, pre-clinical testing and clinical trials, and related investment prior to their commercialization. There can be no         assurance that such devices will be successfully developed, prove to be safe or efficacious in clinical trials, meet applicable regulatory standards, be capable of being produced in commercial quantities at reasonable costs, or be successfully marketed.    Design and Manufacturing Process Risks   While we have substantial experience in designing and manufacturing devices, we may still experience technical difficulties and delays with the design and manufacturing of our or our customers’ products.  Such difficulties could cause significant delays in our production of products.  In some instances, payment by a manufacturing customer is dependent on our ability to meet certain design and production milestones in a timely manner.  Also, some major contracts can be canceled if purchase orders thereunder are not completed when due.  Potential difficulties in the design and manufacturing process that could be experienced by us include difficulty in meeting required specifications, difficulty in achieving necessary manufacturing efficiencies, and difficulty in obtaining materials on a timely basis.   Expansion of Marketing; Limited Distribution   We currently have a limited domestic direct sales force consisting of twenty full-time employees, complemented by a network of clinical support personnel.  We anticipate that we will need to increase our marketing and sales capability significantly to more fully penetrate our target markets, particularly as additional proprietary devices become commercially available.  There can be no assurance that we will be able to compete effectively in attracting and retaining qualified sales personnel or independent manufacturer’s representatives as needed or that such persons will be successful in marketing or selling our services and products.    Product Recalls   If a device that is designed or manufactured by us is found to be defective, whether due to design or manufacturing defects, improper use of the product, or other reasons, the device may need to be recalled, possibly at our expense.  Furthermore, the adverse effect of a product recall on us might not be limited to the cost of a recall.  For example, a product recall could cause a general investigation of ZEVEX by applicable regulatory authorities, as well as cause other customers to review and potentially terminate their relationships with us.  Recalls, especially if accompanied by unfavorable publicity or termination of customer contracts, could result in substantial costs, loss of revenues, and a diminution of our reputation.   RISK FACTORS RELATING TO OUR APPLIED TECHNOLOGY CUSTOMERS   Our success in contract manufacturing depends largely on the success of our customers and their need for our manufacturing services and on the devices designed and manufactured by us for those customers.  Any unfavorable developments or adverse effects on the sales of those devices or such customers’ businesses, results of operations, or financial position could have a corresponding adverse effect on us.  In addition, we sell certain types of medical devices to multiple customers and, to the extent there is an unfavorable development affecting the sales of any such type of device generally, the adverse effect of such development on us would be more substantial than that presented by the decline in sales to a single customer for such type of device.  Additionally, we believe that our design and manufacturing customers and their devices (and ours indirectly) are generally subject to the following risks:   Competitive Environment   The medical device industry is highly competitive and subject to significant technological change.  Participation in such industries requires ongoing investment to keep pace with technological developments and quality and regulatory requirements.  These industries consist of numerous companies, ranging from start-up to well-established companies.  Many of our customers have a limited number of products, and some market only a single product.  As a result, any adverse development with respect to these customers’ products may have a material adverse effect on the business and financial condition of such customers,         which may adversely affect those customers’ ability to purchase and pay for their products manufactured by us.  The competitors and potential competitors of our customers may succeed in developing or marketing technologies and products that will be preferred in the marketplace over the devices manufactured by us for our customers or that would render our customers’ technology and products obsolete or noncompetitive.   Emerging Technology Companies   A number of our customers are emerging medical technology companies that have competitors and potential competitors with substantially greater capital resources, research and development staff and facilities, and substantially greater experience in developing new products, obtaining regulatory approvals, and manufacturing and marketing medical products.  Approximately five customers, representing 9% of our revenue in fiscal year 2005, were, in our opinion, emerging medical technology companies.  These customers may not be successful in launching and marketing their products, or may not respond to pricing, marketing, or other competitive pressures or the rapid technological innovation demanded by the marketplace. As a result, these customers may experience a significant drop in product revenues, which may hamper their ability to continue as our customer or even pay for services and products that we have already delivered.   Customer Regulatory Compliance   The FDA regulates many of the devices manufactured by us under the FDC Act, which requires certain clearances from the FDA before new medical products can be marketed.  There can be no assurance that our customers will obtain such clearances on a timely basis, if at all.  The process of obtaining a PMA or a 510(k) clearance from the FDA could delay the introduction of a product to market.  A customer's failure to comply with the FDA’s requirements can result in the delay or denial of its PMA.  Delays in obtaining a PMA are frequent and could result in our customers delaying or canceling orders to us.  Many products never receive a PMA.  Similarly, 510(k) clearance may be delayed, and in some instances, 510(k) clearance is never obtained.   Once a product is in commercial distribution, discovery of product problems or failure to comply with regulatory standards may result in restrictions on the product's future use or withdrawal of the product from the market despite prior governmental clearance.  There can be no assurance that product recalls, product defects, or modification or loss of necessary regulatory clearance will not occur in the future.    Sales of our medical products outside the United States are subject to regulatory requirements that vary widely from country to country.  The time required to obtain clearance for sale in foreign countries may be longer or shorter than that required for FDA clearance, and the requirements may differ.  The FDA also regulates the sale of exported medical devices, although to a lesser extent than devices sold in the United States.  In addition, our customers must comply with other laws generally applicable to foreign trade, including technology export restrictions, tariffs, and other regulatory barriers.  There can be no assurance that our customers will obtain all required clearances or approvals for exported products on a timely basis, if at all.    Medical devices manufactured by us and marketed by our customers pursuant to FDA or foreign clearances or approvals are subject to pervasive and continuing regulation by the FDA and certain state and foreign regulatory agencies.  FDA enforcement policy prohibits the marketing of approved medical products for unapproved uses.  Our customers control the marketing of their products, including representing to the market the approved uses of their products.  If a customer engages in prohibited marketing practices, the FDA or another regulatory agency with applicable jurisdiction could intervene, possibly resulting in marketing restrictions, including prohibitions on further product sales, or civil or criminal penalties.   Changes in existing laws and regulations or policies could adversely affect the ability of our customers to comply with regulatory requirements.  There can be no assurance that we or a customer of ours will not be required to incur significant costs to comply with laws and regulations in the future, or that such customer         or we will be able to comply with such laws and regulations.    Uncertain Market Acceptance of Products   There can be no assurance that the products that we design and manufacture for our customers will gain any significant market acceptance, even if required regulatory approvals are obtained.  Some of our customers, especially emerging technology companies, have limited or no experience in marketing their products and have not made marketing or distribution arrangements for their products.  Our customers may be unable to establish effective sales, marketing, and distribution channels to successfully commercialize their products.   Product and Inventory Obsolescence   Rapid change and technological innovation characterize the marketplace for medical products.  As a result, ZEVEX and our customers are subject to the risk of product and inventory obsolescence, whether from prolonged development, government approval cycles, or the development of improved products or processes by competitors.  In addition, the marketplace could conclude that the task for which a customer’s medical product was designed is no longer an element of a generally accepted diagnostic or treatment regimen.    Customers’ Future Capital Requirements   Some of our customers, especially the emerging medical technology companies, are not profitable and may have little or no revenues, but they have significant working capital requirements.  Such customers may be required to raise additional funds through public or private financings, including equity financings.  Adequate funds for their operations may not be available when needed, if at all.  Insufficient funds may require a customer to delay development of a product, clinical trials (if required), or the commercial introduction of the product or may prevent such commercial introduction altogether.   Uncertainty of Third-Party Reimbursement   Sales of many of the medical devices that are manufactured by us will be dependent in part on availability of adequate reimbursement for those devices from third-party health care payers, such as government and private insurance plans, health maintenance organizations, and preferred provider organizations.  Third-party payers are increasingly challenging the pricing of medical products and services.  There can be no assurance that adequate levels of reimbursement will be available to enable our customers to achieve market acceptance of their products.  Without adequate support from third-party payers, the market for the products of our customers may be limited.   Uncertainty of Market Acceptance of Outsourced Manufacturing of Medical Devices    We believe that acceptance in the marketplace for outsourcing of design and manufacturing of advanced medical products for medical technology companies varies from year to year and is still uncertain.  Many of our potential customers have internal design and manufacturing facilities.  Our engineering and manufacturing activities require that customers provide us with access to their proprietary technology and relinquish the control associated with internal engineering and manufacturing.  As a result, potential customers may decide that the risks of outsourcing engineering or manufacturing are too great or exceed the anticipated benefits of outsourcing.  In addition, medical technology companies that have previously made substantial investments to establish design and manufacturing capabilities may be reluctant to out-source those functions.  If the medical technology industry generally, or any significant existing or potential customer, concludes that the disadvantages of outsourcing manufacturing outweigh the advantages, we could suffer a substantial reduction in the size of one or more of our current target markets, which could have a materially adverse effect on our business, results of operations, and financial condition.              Competition in Outsourced Manufacturing   We face competition from design firms and other manufacturers that operate in the medical device industry.  Many competitors have substantially greater financial and other resources than we do.  Also, manufacturers focusing in other industries may decide to enter into the industries served by us.  Competition from any of the foregoing sources could place pressure on us to accept lower margins on our contracts or lose existing or potential business.  To remain competitive, we must continue to provide and develop technologically advanced manufacturing services, maintain quality, offer flexible delivery schedules, deliver finished products on a reliable basis, and compete favorably on the basis of price and the value that we provide.  There can be no assurance that we will be able to compete favorably with respect to these factors.   Dependence on Major Customers    No assurances can be given that our customers will continue to do business with us or that the volume of their orders for our contract manufactured devices and proprietary products will increase or remain constant.  The loss of several customers, or a significant reduction in the volume of their orders to us, could have a material adverse impact on our operations.  In addition, if one or more of these customers were to seek and obtain price discounts from us for our contract manufactured devices or proprietary products, the resulting lower gross margins on those devices and products could have a materially adverse effect on our overall results of operations.  If any customer with whom we do a substantial amount of business were to encounter financial distress, the customer’s lateness, unwillingness, or inability to pay its obligations to us could result in a materially adverse effect on our results of operations and financial condition.   Early Termination of Agreements   Our agreements with major manufacturing customers generally permit the termination of the agreements before their expiration if certain events occur that are materially adverse to the design, development, manufacture, or sale of the product.  Examples of such events include the failure to obtain or the withdrawal of regulatory clearance or an alteration of regulatory clearance that is materially adverse to the customer or which prohibits or interferes with the manufacture or sale of the products.  The performance of agreements with major customers may be suspended or excused if certain conditions, generally beyond the control of the customer or us (so-called force majeure events), cause the failure or delay of performance.     Our pump usage agreements, under which enteral feeding pumps are placed with users in exchange for a commitment by the user to buy disposable products from us, generally require only monthly commitments, and users can terminate any purchase obligation by returning the pump.  Thus, there is no assurance of continued revenue from pumps placed with such users.   OTHER COMPANY RISKS   Risk of Product Liability   The manufacture and sale of products, especially medical products, entails an inherent risk of product liability.  We maintain product liability insurance with limits of $1 million per occurrence and $2 million in the aggregate and an umbrella policy with a $10 million limit.  There can be no assurance that such insurance is adequate to cover potential claims or that we will be able to obtain product liability insurance on acceptable terms in the future or that any product liability insurance subsequently obtained will provide adequate coverage against all potential claims.  Such claims may be significant in the medical products area where product failure may result in loss of life or injury to persons.  Additionally, we generally provide a design defect warranty and in some instances indemnification to customers for failure to conform to design specifications and against defects in materials and workmanship, which could subject us to a claim under such warranties or indemnification.                Dependence Upon Management   ZEVEX is substantially dependent upon our key managerial, technical and engineering personnel, particularly our two executive officers, David McNally, President and Chief Executive Officer, and Phillip McStotts, Chief Financial Officer and Secretary/Treasurer.  ZEVEX must also attract and retain highly qualified engineering, technical, and managerial personnel.  Competition for such personnel is intense, the available pool of qualified candidates is limited, and there can be no assurance that we will attract and retain such personnel.  The loss of our key personnel could have a material adverse effect on our business, results of operations, and financial condition.  None of our key personnel have employment agreements with ZEVEX.    We carry key-man life insurance on the lives of our Chief Executive Officer and Chief Financial Officer in the amount of $2,000,000 each.  No assurances can be given that such insurance would provide adequate compensation to ZEVEX in the event of the death of either key employee.   Patent Protection   As of December 31, 2005, we held thirty-five U.S. patents and thirty international patents on devices developed by us, with additional U.S. and international patents pending.  Such patents disclose certain aspects of our technologies and there can be no assurance that others will not design around the patent and develop similar technology.  We believe that our devices and other proprietary rights do not infringe on any proprietary rights of third parties.  There can be no assurance, however, that third parties will not assert infringement claims in the future.    Control by Management and Certain Major Shareholders   As of March 13, 2006, the current executive officers and directors of ZEVEX, together with those persons who are the beneficial owners of more than 5% of ZEVEX’s Common Stock, beneficially own or have voting control over approximately 26% of the outstanding Common Stock.  Accordingly, these individuals have the ability to influence the election of ZEVEX’s directors and most corporate actions.  This concentration of ownership, together with other provisions in ZEVEX’s charter and applicable corporate law, may also have the effect of delaying, deterring, or preventing a change in control of ZEVEX.   Suppliers and Shortages of Component Parts   We rely on third-party suppliers for many of the component parts used in manufacturing our own products and those of our customers.  Although component parts are generally available from multiple suppliers, certain component parts may require long lead times, and we may have to delay the manufacture of devices from time to time due to the unavailability of certain component parts.  In addition, even if component parts are available from an alternative supplier, we could experience additional delays in obtaining component parts if the supplier has not met our vendor qualifications.  Component shortages for a particular device may adversely affect our ability either to meet the production plans for our own devices or to satisfy customer orders for that device.  Such shortages and extensions of production schedules may delay the recognition of revenue by us and may in some cases constitute a breach of a customer contract.  If shortages of component parts continue or if additional shortages should occur, we may be forced to pay higher prices for affected components or delay manufacturing and shipping particular devices, either of which could adversely affect subsequent customer demand for such devices.   Customer Conflicts   The medical technology industry reflects vigorous competition among its participants.  As a result, our customers sometimes require us to enter into non-competition agreements that prevent us from manufacturing instruments or components for our customers’ competitors in certain fields of use.  Such restrictions generally apply during the term of the customer’s manufacturing contract and, in some instances, for a period following termination of the contract.  If we enter into a non-competition agreement,         we may be adversely affected if our customer’s product is not successful and we must forgo an opportunity to manufacture a successful product for such customer’s competitor.  Any conflicts among our customers could prevent or deter us from obtaining contracts to manufacture successful products.   Future Capital Requirements   We believe that our existing capital resources and amounts available under our existing bank line of credit will satisfy our anticipated capital needs for the next year (depending primarily on our growth rate and our results of operations).  The commercialization of proprietary products, which is an element of our growth strategy, would require increased investment in working capital and could therefore shorten this period.  Thereafter, we may be required to raise additional capital or increase our borrowing capacity, or both.  There can be no assurance that alternative sources of equity or debt will be available in the future or, if available, will be on terms acceptable to us.  Also, any additional equity financing would result in additional dilution to our shareholders.     Reliance on Efficiency of Distribution and Third Parties   We believe our financial performance is dependent in part on our ability to provide prompt, accurate, and complete services to our customers on a timely and competitive basis.  Accordingly, delays in distribution in our day-to-day operations or material increases in the costs of procuring and delivering products could have an adverse effect on our results of operations.  Any failure of either our computer operating system or our telephone system could adversely affect our ability to receive and process customers’ orders and ship products on a timely basis.  Strikes or other service interruptions affecting Federal Express Corporation, United Parcel Service of America, Inc., or other common carriers used by us to receive necessary components or other materials or to ship our products also could impair our ability to deliver products on a timely and cost-effective basis.   Volatility of Revenue and Product Mix   Our annual and quarterly operating results are affected by volume and timing of customer orders, which vary due to (i) variation in demand for the customers’ products or services as a result of, among other things, product life cycles, competitive conditions, and general economic conditions, (ii) the customers’ attempt to balance their inventory, (iii) the customers’ need to adapt to changing regulatory conditions and requirements, and (iv) changes in the customers’ preference or strategies.  Technical difficulties and delays in the design and manufacturing processes may also affect such results.  The foregoing factors may cause fluctuations in revenues and variations in product mix, which could in turn cause fluctuations in our gross margin.     Under the terms of our contracts with many of our contract manufacturing customers, the customers have broad discretion to control the volume and timing of product deliveries.  Further, the contracts with our customers typically have no minimum purchase requirements.  As a result, production may be reduced or discontinued at any time.  Therefore, it is difficult for us to forecast the level of customer orders with certainty, making it difficult to schedule production and maximize manufacturing capacity.  Other factors that may adversely affect our annual and quarterly results of operations include inexperience in manufacturing a particular product, inventory shortages or obsolescence, increasing labor costs or shortages, low gross margins on particular projects, an increase in lower-margin product revenue as a percentage of total revenues, price competition, and regulatory requirements.  Because our business organization and our related cost structure anticipate supporting a certain minimum level of revenues, our limited ability to adjust the short-term cost structure would compound the adverse effect of any significant revenue reduction.                 Uncertain Protection of Intellectual Property   To maintain the secrecy of some of our proprietary information, we rely on a combination of trade secret laws and internal security procedures.  We typically require our employees, consultants, and advisors to execute confidentiality and assignment of inventions agreements.  There can be no assurance, however, that the common law, statutory, and contractual rights on which we rely to protect our intellectual property and confidential and proprietary information will provide us with adequate or meaningful protection.  Third parties may independently develop products, techniques, or information that are substantially equivalent to the products, techniques, or information that we consider proprietary.  In addition, proprietary information regarding us could be disclosed in a manner against which we have no meaningful remedy.  Disputes regarding our intellectual property could force us into expensive and protracted litigation or costly agreements with third parties.  An adverse determination in a judicial or administrative proceeding or failure to reach an agreement with a third party regarding intellectual property rights could prevent us from manufacturing and selling certain of our products.   Limited Market for Common Stock   Historically, the market for ZEVEX’s Common Stock has been limited due to the relatively low trading volume and the small number of brokerage firms acting as market makers.  ZEVEX’s Common Stock is listed on the NASDAQ Stock Market.  No assurance can be given, however, that the market for the Common Stock will continue or increase or that the prices in such market will be maintained at their present levels.   Possible Volatility of Stock Price   Announcements of technological innovations for new commercial devices by us or our competitors, developments concerning our proprietary rights, or the public concern as to the safety of our devices may have a material adverse impact on our business and on the market price of our Common Stock.  The market price of ZEVEX Common Stock may be volatile and may fluctuate based on a number of factors, including significant announcements by us and our competitors, quarterly fluctuations in our operating results, and general economic conditions and conditions in the medical device industry.  In addition, in recent years the stock market has experienced extreme price and volume fluctuations, which have had a substantial effect on the market prices for many medical device companies and are often unrelated to the operating performance of such companies.   Issuance of Additional Shares for Acquisition or Expansion   Any future major acquisition or expansion by us may include the issuance of additional common shares or other stocks or instruments that may be authorized without shareholder approval.  The issuance of subsequent securities may also result in substantial dilution in the percentage of the Common Stock held by existing shareholders at the time of any such transaction.  Moreover, the shares or warrants issued in connection with any such transaction may be valued by our management based on factors other than the trading price on the NASDAQ Stock Market.    Impact of Anti-Takeover Measures; Possible Issuance of Preferred Stock; Classified Board   Certain Provisions of our Certificate of Incorporation and Bylaws and the Delaware General Corporation Law may have the effect of preventing, discouraging, or delaying a change in the control of ZEVEX and may maintain the incumbency of our Board of Directors and management.  Such provisions could also limit the price that certain investors might be willing to pay in the future for shares of ZEVEX Common Stock.  Pursuant to our Certificate of Incorporation, the Board of Directors is authorized to fix the rights, preferences, privileges, and restrictions, including voting rights, of unissued shares of ZEVEX Preferred Stock and to issue such stock without any further vote or action by our stockholders.  The rights of the holders of ZEVEX Common Stock will be subject to and may be adversely affected by the rights of the holders of any Preferred Stock that may be created and issued in the future.             In addition, stockholders do not have the right to cumulative voting for the election of directors.  Furthermore, our Certificate and Bylaws provide for a staggered board whereby only two to three of the total number of directors are replaced or re-elected each year.  The Certificate also provides that the provisions of the Certificate relating to the number, vacancies, and classification of the Board of Directors may only be amended by a vote of at least 66 2/3% of the shareholders.  Finally, the Bylaws provide that special meetings of the stockholders may only be called by the President or any Director of ZEVEX or pursuant to a resolution adopted by a majority of the Board of Directors.   ZEVEX is subject to Section 203 of the Delaware General Corporation Law (“Section 203”), which restricts certain transactions and business combinations between a corporation and an “Interested Stockholder” owning 15% or more of the corporation’s outstanding voting stock for a period of three years from the date the stockholder becomes an Interested Stockholder.  Subject to certain exceptions, unless the transaction is approved in a prescribed manner, Section 203 prohibits significant business transactions such as a merger with, disposition of assets to, or receipt of disproportionate financial benefits by the Interested Stockholder, or any other transactions that would increase the Interested Stockholder’s proportionate ownership of any class or series of the corporation’s stock.   Foreign Exchange, Currency, and Political Risk   Our international business is subject to risks customarily encountered in foreign operations, including changes in a specific country’s or region’s political or economic conditions, nationalization, trade protection measures, import or export licensing requirements, the overlap of different tax structures, unexpected changes in regulatory requirements, or other restrictive government actions such as capital regulations.  We are also exposed to foreign currency exchange rate risk inherent in our foreign sales commitments and anticipated foreign sales because the prices charged for our products are denominated in U.S. dollars.  Consequently, our foreign sales commitments and anticipated sales could be adversely affected by an appreciation of the U.S. dollar relative to other currencies.
-- 13
UNRESOLVED STAFF COMMENTS     None
PROPERTIES     Our executive offices, administrative offices, and manufacturing facility are located in our 51,000 square foot, mixed-use building in Salt Lake City, Utah.  This building was constructed in 1997 to our specifications and is subject to an Industrial Development Bond (see “Management’s Discussion and Analysis of Financial Condition and Results of Operations, Liquidity and Capital Resources”).  The building is situated on nearly four acres of land a few miles from the downtown area.  It allows quick access to two major interstate freeways and to the Salt Lake International Airport.  We currently utilize approximately 70% of the building’s available space and believe that the building will be adequate to serve our needs through the end of the year 2006. We own approximately 3.47 vacant acres adjacent to our facility.
LEGAL PROCEEDINGS       The following is a brief description of certain legal proceedings to which we a party or to which our properties are subject.  In management’s opinion, the legal proceeding described below is not expected to have a material adverse effect on our business, financial condition, results of operations or liquidity.     On February 23, 2006, we filed a complaint in the United States District Court, alleging the infringement of certain patents by medical device manufacturer.  The complaint alleges that the manufacturer makes, sells and offers for sale infusion pumps which utilize patented technology of ZEVEX.  Currently we are pursuing possible resolution to this matter.
SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS     None.   PART II
MARKET FOR REGISTRANT’S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS     ZEVEX’s Common Stock is traded on the National Market system of The NASDAQ Stock Market, under the symbol ZVXI.  As of March 13, 2006, there were 139 holders of record of ZEVEX’s Common Stock (calculated without reference to individual participants in securities position listings).  Based on the number of proxy materials requested by brokers and other record holders for distribution to beneficial owners for ZEVEX’s 2005 Annual Meeting, we estimate there are roughly 1,550 beneficial owners of ZEVEX Common Stock.  ZEVEX has never declared or paid any cash dividends on its Common Stock.  ZEVEX currently intends to retain all future earnings to finance future growth and does not anticipate paying any cash dividends in the foreseeable future.  We have a negative covenant in our bank line of credit agreement that prevents the payment of any cash dividend without prior approval of the bank.    The following table lists the high and low sales prices for ZEVEX Common Stock for each full quarterly period since January 1, 2004.           2005   2004         High   Low   High   Low     1st Quarter   4.47   3.52   4.12   2.85     2nd Quarter   4.50   3.10   4.14   2.55     3 rd Quarter   5.10   3.56   6.38   3.11     4th Quarter   14.49   4.72   6.50   3.14
SELECTED FINANCIAL DATA     SELECTED FINANCIAL DATA - FIVE-YEAR REVIEW   The following selected statement of operations data for the years ended December 31, 2005, 2004, and 2003, and the balance sheet data as of December 31, 2005 and 2004, are derived from the audited consolidated financial statements included in this report and should be read in conjunction with those consolidated financial statements and notes thereto.  The selected statement of operations data for the years ended December 31, 2002 and 2001, and the balance sheet data as of December 31, 2003, 2002, and 2001, are derived from the audited consolidated financial statements of ZEVEX, which are not included herein, and are qualified by reference to such financial statements and the notes thereto.  The selected consolidated financial data set forth below is also qualified in its entirety by, and should be read in conjunction with the Consolidated Financial Statements and Notes thereto and “Management's Discussion and Analysis of Financial Condition and Results of Operations” included in Item 7 of this report.                                 Fiscal Year Ended December 31           2005   2004   2003   2002   2001     Statement of Operations Data                         Revenues   $30,273,922   $23,634,355   $25,869,876   $25,495,733   $29,882,075     Gross profit   11,349,552   8,456,978   8,323,795   11,119,989   12,052,298     Selling, general and administrative expenses   8,091,996   7,142,513   8,316,822   9,124,197   10,100,735     Research and development expenses   1,208,466   1,430,692   1,817,581   1,289,609   932,731     Asset and goodwill impairment   --   --   1,566,967   --   --     Operating income (loss)    2,049,090   (116,227)   (3,377,575)   706,183   1,018,832     Loss on sale of business   --   --   (4,692,445)   --   --     Impairment loss on marketable securities   (27,525)   --   --   --   (917,628)     Other expenses   112,592   93,972   276,234   486,664   688,414     Provision (benefit) for  income taxes   3,595   (31,222)   (68,712)   5,216   (99,507)     Net income (loss)    1,905,378   (178,977)   (8,277,542)   214,303   (487,703)     Net income (loss) per share basic   .56   (.05)   (2.43)   .06   (.14)     Weighted average shares outstanding    3,416,828   3,400,964   3,400,964   3,414,846   3,431,639     Net income (loss) per share diluted   .52   (.05)   (2.43)   .06   (.14)     Weighted average shares outstanding,  assuming dilution     3,675,207     3,400,964     3,400,964     3,418,278     3,431,639                                   2005   2004   2003   2002   2001     Balance Sheet Data                         Total assets   $20,850,381   $17,400,982   $19,732,085   $28,798,236   $33,639,146     Total current liabilities    3,964,247   2,711,603   4,688,891   5,679,446   5,918,660     Long-term debt (less current portion)   1,810,143   1,966,362   2,119,608   1,662,536   6,411,351     Stockholders' equity   15,075,991   12,723,017   12,923,586   21,198,061   21,032,401     Please refer to Item 7 of this report for a discussion of the main factors causing the substantial changes in certain of the items set forth above, particularly when comparing the year 2005 to earlier periods.  Also refer to Item 7 of this report for a discussion of Factors that May Affect Future Results, which describe material uncertainties that might cause the items set forth above to not be indicative of our future financial condition or results of operations.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS     Overview   Through our two divisions, we engage in the business of designing, manufacturing, and distributing medical devices.  Our Therapeutics division markets enteral nutrition delivery devices.  Our Applied Technology division designs and manufactures advanced medical components and systems for other medical technology companies. Until its sale on December 31, 2003, our Physical Evaluation division manufactured and marketed physical evaluation testing systems.  Please refer to Note 12 of the Audited Consolidated Financial Statements for discussion of our business segments.    Our Therapeutics division products include ambulatory enteral feeding pumps and related disposable sets for mobile patients, as well as stationary enteral feeding pumps and disposable sets.  We entered the home health care segment of the enteral nutrition delivery market in 1996 with the introduction of the EnteraLite( ambulatory enteral feeding pump, which gained market share due to its superior mobility and state-of-the-art features.  We believe that by improving the convenience of nutrition delivery, first with the EnteraLite( and now with the EnteraLite® Infinity® we can contribute to better clinical outcomes and improved quality of life for enteral patients.     In 2005, our Therapeutics division produced revenue of $16.9 million, achieving growth of 35% over 2004.  Based upon the introduction of the EnteraLite® Infinity® product line and the continued sales strength of our         original EnteraLite® product line, our domestic sales of ambulatory products produced revenue of $9.2 million, achieving growth of 19%, during 2005, compared with growth of 8% in 2004.  The most significant growth in our Therapeutics division in 2005, however, came from the global expansion of sales of our Therapeutics product line through Nutricia Clinical.  Combining our international EnteraLite( and EnteraLite® Infinity® revenue with domestic revenue, the total ambulatory product line growth was 58% in 2005.  As we forecasted at the end of 2004, we generated more than $3.5 million in new sales to Nutricia Clinical during the launch of the Flocare Infinity in Europe in the second half of 2005, driving total international Therapeutics revenue to a record of more than $5 million for the year.     Our growth in our ambulatory enteral feeding products has been partially offset by decreases in sales of our stationary pumps.  Our planned growth and expansion into the long-term care market has not materialized due to continued downward competitive pricing pressure in this market segment.  The result is that our revenue in the stationary enteral feeding pump business decreased by approximately 14% in 2005.     Our Applied Technology division began in 1987, offering an increasingly broad array of specialized design and manufacturing services to large, multinational medical companies.  Our core technologies are in the areas of sensing, fluid management and surgical ultrasound.  Our customers typically incorporate our components and systems under private label with their primary products.     In 2005, our largest Applied Technology customers posted market share gains, from which we benefited.  As a result, the Applied Technology division produced revenue of $13.4 million in 2005, achieving growth of 20% during the year, compared with growth of 7% in 2004.     During 2003, we evaluated our business opportunities and restructured our operations to focus on our core market offerings of ambulatory enteral feeding (our Therapeutics division) and contract manufacturing services (our Applied Technology division).  As part of this effort we established a lean manufacturing philosophy including the transition from batch processing to continuous flow production, realigned our operating segments to more accurately reflect our current business, and sold the Physical Evaluation business in December 2003.   The sale of our Physical Evaluation business was accomplished by the sale of all the issued and outstanding capital stock of JTech Medical Industries, Inc. our wholly-owned operating subsidiary.  The transaction was effected by a Stock Purchase Agreement dated December 31, 2003 by and between us and Mr. Leonard C. Smith, a former employee, officer and director of ZEVEX. Please refer to Note 2 in the Audited Consolidated Financial Statements for discussion of the sale.   During the first quarter of 2005, we completed a multi-year research and development project leading to the introduction of our next-generation enteral feeding pump, the EnteraLite® Infinity®, at the American Society of Parenteral and Enteral Nutrition Annual Conference in January 2005.  The EnteraLite® Infinity® provides patients in hospitals, nursing homes, or at home with the lightest, most accurate, and longest lasting, battery-operated pump available.    In June 2005, we received a Silver Medical Design Excellence Award for the EnteraLite® Infinity® at the Medical Design & Manufacturing East trade show in New York City.  We also developed and manufacture a custom optoelectronic sensor for a product of Baxter Healthcare that received a 2005 Gold Medical Design Excellence Award at the same trade show.     In August 2005, Nutricia Clinical, the clinical nutrition division of Royal Numico, announced the European launch of the Flocare® Infinity® enteral pump.  Nutricia Clinical is our exclusive distributor for that private-label version of our EnteraLite® Infinity® enteral feeding pump.   Results of Operations   As an aid to understanding our operating results, the following table sets forth, for the periods indicated, the relative percentages that certain items in the statement of operations bear to revenue.              Year Ended December 31 Statement of Operations Data -- Percentage of Revenue          2005   2004   2003   2002   2001     Revenue   100%   100%   100%   100%   100%     Gross profit   37%   36%   32%   44%   40%     Selling, general and administrative expenses     27%     30%     32%     36%     34%     Research and development expenses   4%   6%   7%   5%   3%     Asset and goodwill impairment   --%   --%   6%   --%   --%     Operating income (loss)   --%   --%   (13)%   3%   3%     Loss on sale of business   --%   --%   (18)%   --%   --%     Impairment loss on securities   --%   --%   --%   --%   (3)%     Other income/(expense)   --%   --%   (1)%   (2)%   (2)%     Income (loss) before income taxes   --%   (1)%   (32)%   1%   (2)%     Provision (benefit) for income taxes   --%   --%   --%   --%   --%     Net income (loss)   6%   (1)%   (32)%   1%   (2)%     Fiscal Year 2005 Compared to Fiscal Year 2004   Our revenue increased by approximately 28% during 2005, to $30,273,922, compared to $23,634,355 for 2004.  Therapeutics products generated 56% and sales of Applied Technology contract manufactured products generated 44% of total revenue during 2005.  During 2005, two customers accounted for approximately 14% and 13%, respectively, of our revenue.  During 2004, one customer accounted for approximately 11% of our revenue.   Our Therapeutics division revenue increased 35% to $16,899,383 during 2005, compared to $12,488,953 in 2004.  The increase in revenue from last year is due to an increase of 165%, in our international Therapeutics revenue largely due to Nutricia Clinical.  Nutricia Clinical is our exclusive European distributor for the Flocare® Infinity®, a private-label version of our EnteraLite® Infinity®  Our domestic EnteraLite® Infinity® and EnteraLite( portable feeding pump and disposable set revenue increased 19% over 2004.  These increases were partially offset by a decrease of 14%, in sales of our stationary enteral feeding delivery products within our Therapeutics division.     Our Applied Technology division revenue increased 20% to $13,374,539 during 2005, compared to $11,145,402 in 2004.  Specifically, during 2005, sensor revenue increased approximately 42%, and surgical handpiece revenue increased 12% over 2004, because our largest customers for these products posted market share gains, and substantially increased purchases of our products from which we benefited.  Applied Technology engineering revenue increased 21% during 2005 compared to 2004.  These increases more than offset a decrease in medical system revenue of approximately 8%.   Our gross profit as a percentage of revenue was approximately 37% for 2005, compared to 36% for 2004.    We attribute this increase primarily to the different product mix delivered during the year and to the  spread of  fixed overhead manufacturing costs over our increased revenue.  Please refer to Note 12 of the Audited Consolidated Financial Statements for discussion of our business segments including gross profit and the Company’s definition of contribution margin.    Depreciation and amortization expenses decreased to $710,612 in 2005 from $857,731 in 2004.  The decrease is primarily due to the various ages of our depreciable assets.   Selling, general and administrative expenses increased during 2005 to $8,091,996, from $7,142,513 in 2004.  With our revenue gains in 2005, this increase was actually a decrease as a percentage of revenue to 27%, as compared to 30% of revenue in 2004.  The dollar increase is primarily related to increases in recruiting, personnel and insurance costs.              We combine the resources of our full-time engineers with several independent contractors to perform research and development projects.  We invested $1,208,466 in the research and development of new products and technologies during 2005, a decrease from the $1,430,692 invested in 2004.  This decrease was a result of our launch of the EnteraLite® Infinity® enteral feeding pump, which consumed considerable research and development resources in 2004.  The decrease does not reflect reduced efforts to develop and introduce new proprietary products for our Therapeutics division or proprietary component technologies for our Applied Technology business.  We expect research and development costs to be approximately 5% of revenue during 2006.   We had operating income of $2,049,090, or 7% of revenue in 2005, compared to an operating loss of $116,227, or 0.5% of revenue in 2004.  Our net income was $1,905,378, in 2005, or 6% of revenue, compared to a net loss of $178,977 in 2004, or 1% of revenue.  The increase in operating and net income during 2005, as compared to 2004, is primarily related to the increase in revenue in 2005 and the resulting increase in our gross profit, which was partially offset by increased selling, general and administrative expenses.    We had income tax expense of $3,595 in 2005 compared to an income tax benefit of $31,222 in 2004.  Income tax expense in 2005 represents minimum tax payments due to the various states in which we are required to file.  The income tax benefit in 2004 is a result of an income tax refund partially offset by minimum tax payments due to the various states in which we are required to file.  For 2005, our effective tax rate differed from the statutory rate largely as a result of taxable income generated, offset by a decrease in our valuation allowance (see below), and research and development tax credits.  For 2004, our effective tax rate differed from the statutory rate largely as a result of an increase in our valuation allowance (see below), and research and development tax credits.  We were able to realize a portion of the deferred tax asset related to our net operating loss carryforward in 2005, which resulted in a partial reversal of the related valuation allowance.  We expect to be able to do so in 2006 as well.  The Company generated a net operating loss carryforward in 2005 of $396,000 as a result of employee stock option exercises.  The Company established a valuation allowance against this amount, which was recorded to additional-paid-in-capital.  When this valuation allowance is reversed, the impact will also be recorded to additional-paid-in-capital.  The decrease in 2005 in the deferred tax valuation allowance was $612,000.    We have federal net operating loss carryforwards totaling approximately $345,000 that begin to expire in 2023.  We have state net operating loss carryforwards totaling approximately $8,846,000 that begin to expire in 2016.  We have a federal and state charitable contribution carryforward totaling approximately $4,947,000 that is only recognizable if we have taxable income.  This carryforward expires in 2007.  Finally, we have a federal capital loss carryforward of approximately $9,901,000 that begins to expire in 2006.   At December 31, 2005 and December 31, 2004, we had net current deferred tax assets of $0.  Realization of our deferred tax assets is dependent on our ability to generate taxable income in the year the assets are realized.  Under FAS 109 Accounting for Income Taxes, guidance has been issued relating to cumulative losses in recent years.  Under this guidance, when there is a cumulative pretax loss for financial reporting for the current and two preceding years and a company does not have objective planning strategies designed to realize its deferred tax assets, generally no deferred tax asset should be recognized.  In following this guidance management established a full valuation allowance for all deferred tax assets in 2003.     At December 31, 2005, we had a backlog of approximately $8,142,549 on orders for medical devices to be manufactured for other medical technology companies, as compared to a backlog at December 31, 2004 of $5,364,640.  We estimate that approximately 90% of the backlog will be shipped before December 31, 2006.  Our backlog is for contract manufacturing only and can be significantly affected by the timing of annual or semi-annual purchase orders placed by our customers.  During the past year, several of our Applied Technology customers have adopted lean manufacturing philosophies, which results in the elimination of large, advance-notice purchase orders and replacement with just-in-time, frequent kanban         deliveries.  While more efficient for the supply chain, this can greatly reduce our backlog figures.   Our annual and quarterly operating results are affected by acceptance in the markets for our proprietary and contract manufactured products, including the volume and timing of customer orders, which vary due to (i) variation in demand for the customers’ products or services as a result of, among other things, product life cycles, competitive conditions, and general economic conditions, (ii) the customers’ attempt to balance their inventory, (iii) the customers’ need to adapt to changing regulatory conditions and requirements, and (iv) changes in the customers’ preferences or strategies.  Technical difficulties and delays in the design and manufacturing processes may also affect such results.  The foregoing factors may cause fluctuations in revenue and variations in product mix, which could in turn cause fluctuations in our gross margin.   Fiscal Year 2004 Compared to Fiscal Year 2003   Revenue for the Applied Technology and Therapeutics divisions increased by approximately 3% during 2004, compared to 2003.  Revenue for these two divisions was $23,634,355 during 2004, compared to $22,853,887 for 2003.  This comparison does not include revenue from the Physical Evaluation division, which was sold on December 31, 2003.  Revenue in 2003 from the Physical Evaluation division was $3,015,989.   The increase in revenue in 2004 over 2003, excluding the Physical Evaluation business, was largely due to a 7% increase in the Applied Technology division revenue.  Specifically, surgical handpiece and sensor revenue held steady during the year, and medical systems revenue increased by approximately $2,200,000 for 2004.  These increases more than offset lower engineering revenue, as certain programs moved from engineering to manufacturing.  Our Therapeutics division revenue increased 1% during 2004, compared to 2003.  Specifically, the EnteraLite( portable feeding pump and disposable set revenue in this division increased 8%.  Also, our international Therapeutics revenue increased approximately 5% during the year.  This growth more than offset an 18% decrease in stationary disposable set revenue for the year, primarily related to the continued downward competitive pricing.         Applied Technology contract manufactured products generated 47% of total revenue during 2004, and sales of our proprietary Therapeutics products generated 53% of revenue during the year.  Excluding revenue from the Physical Evaluation business which has been sold, Applied Technology revenue was 46% of total revenue for 2003 and our proprietary Therapeutics products generated 54% of revenue.  If sales from the Physical Evaluation division were included in this comparison, proprietary product revenue would have been 60% of total revenue and Applied Technology revenue would have been 40% of total revenue in 2003.  During 2004, one customer accounted for revenue in excess of 10% and in 2003, no single customer accounted for over 10% of our revenue.    Our gross profit as a percentage of revenue was approximately 36% for 2004, compared to 32% for 2003.    We attributed the changes in gross profit percentage from 2004 to 2003 to expenses that were recorded in 2003 that were non-recurring in 2004, such as the write-off of discontinued products and non-recurring manufacturing engineering costs associated with establishing new production lines.     Depreciation and amortization expenses decreased to $857,731 in 2004 from $1,582,120 in 2003 (excluding impairment).  We recorded an impairment charge of $1,566,967 in 2003.  See Note 1 to the Audited Consolidated Financial Statements under Goodwill, and Impairment of Long-Lived Assets for more information on the effect of the impairment. The decrease was primarily due to the impairment loss recorded on assets in 2003, resulting in a subsequent decline in depreciation expense.    Selling, general and administrative expenses decreased during 2004 to $7,142,513, 30% of revenue, as compared to $8,316,822 for 2003, 32% of revenue.  The decrease was primarily related to the reduction in personnel from the sale of the Physical Evaluation business, although the decrease was partially offset in the second and third quarters of 2004 by non-recurring legal expenses incurred in the amount of approximately $340,000, for the negotiations and drafting of the strategic distribution, manufacturing, and services         agreements with Royal Numico N.V.    We combine the resources of our full-time engineers with several independent contractors, to perform research and development projects.  We invested $1,430,692 in the research and development of new products during 2004, compared to $1,817,581, which included approximately $763,000 from the Physical Evaluation division in 2003.  The decrease in research and development costs was primarily due to the elimination of product developments costs related to the Physical Evaluation division sold in 2003.   We had an operating loss of $116,227, or 0.5% of revenue in 2004, compared to an operating loss of $3,377,575, 13% of revenue in 2003.  The change in operating loss was due to the factors described above, including a higher gross profit percentage, lower general and administrative costs, and the asset and goodwill impairment in 2003.  We had a net loss of $178,977, or 1% of revenue in 2004, compared to a net loss of $8,277,542, or 32% of revenue in 2003.  The decrease in the net loss during 2004, as compared to 2003, was due to the factors noted above, as well as a decrease in interest expense, as we continued to reduce our debt from 2003, the reduction in research and development costs, the recognition of certain deferred tax assets (see below), and the loss on the sale of the Physical Evaluation business in the amount of $4,692,445 in 2003.   We had an income tax benefit of $31,222 in 2004, compared to an income tax benefit of $68,712 for 2003.  The majority of the income tax benefit in 2004 was a result of an income tax refund that was originally provided for as part of the deferred tax asset valuation allowance.  For 2004, our effective tax rate differed from the statutory rate largely as a result of an increase in our valuation allowance, and research and development tax credits.  For 2003, our effective tax rate differed from the statutory rate largely as a result of an increase in our valuation allowance, research and development tax credits, and permanent asset basis differences.     On December 31, 2003, the Company completed the sale of its Physical Evaluation business.  The transaction was accomplished through the sale of all the issued and outstanding capital stock of JTech previously a wholly owned subsidiary of the Company.  The transaction was effected by a Stock Purchase Agreement dated December 31, 2003 by and between the Company and Mr. Leonard C. Smith, a former employee, officer and director of the Company, for a purchase price of $1.2 million.  Cash of $1,164,500 was received in 2004 and $35,500 was received in February 2005 when the Company satisfied certain obligations to JTech as set forth in the Stock Purchase Agreement.  Such obligations included the requirement to deliver inventory, upon completion of production, and certain other equipment.  Deferred revenue of $324,000 was recorded related to these obligations, all of which was realized in 2004.   The Company also received additional payments from the purchaser based upon specifically identified JTech product sales in 2005.  A loss on the sale of this business in the amount of $4,692,445 was recorded and is shown separately on the 2003 consolidated statement of operations.  Such loss consists of the write-off of goodwill and other intangibles as discussed in Note 1 to the Audited Consolidated Financial Statements as well as the write-off of certain other JTech related assets totaling approximately $242,000 and the accrual of legal costs associated with this transaction.     Liquidity and Capital Resources   Our primary sources of liquidity have consisted of cash flow from operations, borrowings under our revolving line of credit and other financial arrangements described below.  In prior years, we also have increased working capital through the issuance of stock and we may do so in the future.     Cash flows provided from operating activities for 2005 were $1,854,575, compared to $1,009,418 for 2004.  In 2005, cash provided by operating activities was primarily associated with our net income, an increase in accounts payable and other accrued liabilities, partially offset by an increase in accounts receivable balances due to the substantial increase in revenue during the second half of the year.  In 2004, cash provided by operating activities was primarily associated with our improved collection procedures, an increase in accounts payable, and the collection of an income tax receivable, partially offset by a decrease in deferred         revenue and an increase in inventory.     Our working capital at December 31, 2005 was $7,850,267, compared to $5,959,929 at December 31, 2004.  The increase in working capital in 2005 from 2004 is primarily due to the increase in net income,  the resulting increase in accruals, receivable, and cash.   The portion of working capital represented by cash at such dates was $1,284,218 and $212,859 respectively.       We maintain a line of credit arrangement with a financial institution with availability of $3 million.  The line matures on May 29, 2006.  We expect that we will be able to renew our line of credit in May 2006.  The line of credit is collateralized by accounts receivable and inventory and bears interest at the rate of LIBOR plus 2.40%, which was 6.79% at December 31, 2005 and at prime rate of 5.25% at December 31, 2004. We had a zero balance on this line of credit at December 31, 2005 and 2004.    On April 18, 2001, the Company entered into a Term Loan Agreement with a bank for the amount of $1,000,000.  The agreement as amended, is secured by the Company’s manufacturing facility.  The note is due May 15, 2008 and is being amortized over a thirteen-year term, at an interest rate of 5.4%. The outstanding balance at December 31, 2005 was $766,362, of which $56,219 is classified as current.   On October 30, 1996, the Company completed a transaction defined as “Murray City, Utah, Adjustable Rate Industrial Development Revenue Bonds, Series 1997 (ZEVEX, Inc. Project)” in the amount of $2,000,000. The bonds are secured by an irrevocable Letter of Credit issued by a bank, which is subject to expiration no later than May 30, 2008.  The bonds bear interest at an adjustable rate based on the weekly tax-exempt floater rate, as determined by the remarketing agent.  During 2005, the interest paid monthly ranged from 1.83% to 3.55% (APR), with an average rate for 2005 of 2.23%.  The bonds mature on October 1, 2016. Principal reductions occur in the amount of $100,000 per year. The outstanding balance was $1,200,000 at December 31, 2005, of which $100,000 is classified as current.   The following is a summary of the Company’s debt and other long-term obligations:          Principal Payment due by period       Contractual Obligation       Total     Less than 1 –year   More than 1- year   More than 2- year   More than 3- year   More than 4- year     More than 5- year     Industrial Development Bond        $1,200,000       $100,000       $100,000       $100,000       $100,000       $100,000       $700,000     Other  Long-term debt     766,362     56,219     59,358     650,785     -     -     -     Total   $1,966,362   $156,219   $159,358   $750,785   $100,000   $100,000   $700,000       Purchases of leasehold improvements to our facilities, tooling and new engineering, production and testing equipment totaled $977,316 for 2005, compared to $379,886 for 2004 and $610,685 in 2003.  We expect to spend approximately $1,200,000 during 2006 for additional manufacturing equipment and software, for normal replacement of aging equipment, manufacturing tooling related to our proprietary products, and improvements to our manufacturing area.     Our expected principal liquidity requirements are working capital, investments in capital expenditures, and debt reduction.  We believe our sources of liquidity are sufficient for operations during the coming twelve months.  These sources include our projected cash from operations and, if necessary, draws from our existing revolving line of credit.   Off-Balance Sheet Items   We have no off-balance sheet items.            Other   As part of a nationwide investigation into billing practices associated with enteral nutrition delivery products, particularly in regard to billing practices for pumps and disposable delivery sets, on July 2, 2001, the U.S. Office of Inspector General (OIG), served a subpoena on the ZEVEX, Inc. subsidiary.  According to published reports, the investigation involved most manufacturers, distributors and health care service providers in the United States enteral pump industry and similar subpoenas were served on many of those parties.  The subpoena requested documents relating to our enteral pump customers’ marketing and billing practices.  We responded to the subpoena.  Since October of 2001 we have not been contacted further by the OIG, although we understand the investigation is proceeding and we intend to cooperate with the investigation when contacted again.  At this time we are uncertain as to any future impact this investigation will have on our operations or financial position.   Inflation and Changing Prices   We have not been, and in the near term are not expected to be, materially affected by inflation or changing prices.    Critical Accounting Policies and Estimates   In response to the SEC’s Release numbers 33-8040 “Cautionary Advice Regarding Disclosure About Critical Accounting Policies” and 33-8056, “Commission Statement about Management's Discussion and Analysis of Financial Condition and Results of Operations,” we have identified the following critical accounting policies that affect the more significant judgments and estimates used in the preparation of the consolidated financial statements. The preparation of the consolidated financial statements in conformity with U.S. generally accepted accounting principles requires us to make estimates and judgments that affect our reported amounts of assets and liabilities, revenues and expenses, and related disclosures.  Our significant accounting policies are included in Note 1 to the Audited Consolidated Financial Statements.   We evaluate our estimates and judgments on an on-going basis. We base our estimates on historical experience and on assumptions that we believe to be reasonable under the circumstances.  Our experience and assumptions form the basis for our judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may vary from what we anticipate and different assumptions or estimates about the future could change our reported results. We believe the following accounting policies are the most critical to us, in that they are material to the portrayal of our financial statements and they require our most difficult, subjective, or complex judgments in the preparation of our consolidated financial statements:   Revenue Recognition   We recognize revenue from products sold directly to end customers when persuasive evidence of an arrangement exists, the price is fixed or determinable, shipment is made and title has passed, and collectibility is reasonably assured. If such criteria are not met, revenue is deferred.     We recognize revenue from products sold to distributors when persuasive evidence of an arrangement exists, the price is fixed or determinable, shipment is made and title has passed, and collectibility is reasonably assured.  If such criteria are not met, revenue is deferred.  There are no post-shipment obligations other than warranty service related to the product, no rights to return the product unless it is defective, no price protection, and no volume pricing rebates or stock rotation rights.   Contracts to perform engineering design and product development services are generally performed on a time and materials basis.  Revenue generally is recognized as milestones are achieved.               We account for revenue from software transactions pursuant to SOP No. 97-2, Software Revenue Recognition, as amended by SOP No. 98-4 and SOP No. 98-9.  SOP No. 97-2 requires that revenue recognized from software arrangements be allocated to each element of the arrangement based on the relative fair values of the elements, such as software products, upgrades, enhancements, post-contract customer support, installation, or training.  Under SOP No. 97-2, the determination of fair value is based on objective evidence, which is specific to the vendor. If such evidence of fair value for each element of the arrangement does not exist, all revenue from the arrangement is deferred until such time that evidence of fair value does exist or until all elements of the arrangement are delivered.  As of December 31, 2003 we sold our Physical Evaluation business and no longer sell software or related services.    Allowance for Doubtful Accounts and Sales Returns   As a general policy, collateral is not required for accounts receivable; however, we periodically monitor the need for an allowance for doubtful accounts based upon expected collections of accounts receivable, historical bad debt rates, and specific identification of uncollectible accounts.  Based on these factors, we record an allowance to provide for accounts that we believe may not be ultimately collectable.  Additionally, customers’ financial condition and credit worthiness are regularly evaluated.  Historically losses on collections have not been material.  We also record a provision for estimated sales returns and allowances on products we have sold.  These estimates are based on historical sales returns and other known factors.  If the historical data we use to calculate these estimates does not properly reflect future returns, revenue could be overstated or understated.  As of December 31, 2005 and 2004, we have recorded allowances for doubtful accounts and sales returns of $130,000 and $192,000, approximately 2.3% and 5.1% respectively of gross accounts receivable.   Product and Inventory Obsolescence    Rapid change and technological innovation characterize the marketplace for medical products.  As a result, we and our customers are subject to the risk of product and inventory obsolescence, whether from prolonged development, government approval cycles, or the development of improved products or processes by competitors.  In addition, the marketplace could conclude that the task for which a customer’s medical product was designed is no longer an element of a generally accepted diagnostic or treatment regimen.  Accordingly, we write down inventory that we believe is excess or obsolete.  Inventories are stated at the lower of cost or market; cost is determined using the first-in, first-out method.  As of December 31, 2005 and 2004, we have recorded an excess and obsolete reserve of $284,000 and $270,000, which is approximately 5.8% and 5.6%, respectively of gross inventories.    Warranty   We record a provision for estimated warranty reserve on products we have sold.  These estimates are based on historical warranty expenses and other known factors.  If the historical data we use to calculate these estimates does not properly reflect future warranty expenses, expenses could be understated or overstated.  We have recorded a warranty expense allowance in the amount of $152,000 as of December 31, 2005 and $155,000 as of December 31, 2004.     Impairment   We have made acquisitions in the past that included a significant amount of fixed assets, goodwill, and other intangible assets. The cost of the acquired companies was allocated first to identifiable assets based on estimated fair values.  Intangible assets consist of goodwill, contracts, patents, and licenses.     Effective in 2002, goodwill is no longer amortized but is subject to an annual (or, under certain circumstances, more frequent) impairment test, based on its estimated fair value. Other intangible assets will generally continue to be amortized over their useful lives and also will be subject to an impairment test         based on estimated fair value. Estimated fair value is typically less than values based on undiscounted operating earnings because fair value estimates include a discount factor in valuing future cash flows. There are many assumptions and estimates underlying the determination of an impairment loss. Another estimate using different, but still reasonable assumptions could produce a significantly different result. Therefore, impairment losses could be recorded in the future.   Currently, we assess the impairment of fixed assets and identifiable intangibles whenever events or changes in circumstances indicate that the carrying value may not be recoverable.  Factors we consider important that could trigger an impairment review include the following:          •   A significant underperformance relative to expected historical or projected future operating results;          •   A significant change in the manner of how we use the acquired asset or the strategy for our overall business;          •   A significant negative industry or economic trend.     When we determine that one or more of the above indicators of impairment exist, we evaluate the carrying amounts of the affected assets.  The evaluation, which involves significant management judgment, is based on various analyses including cash flow and profitability projections.  To the extent such projections indicate that future undiscounted cash flows are not sufficient to recover the carrying amounts of the related long-lived assets, the carrying amount of the underlying assets will be reduced, with the reduction charged to expense, so that the carrying amount is equal to fair value, primarily determined based on future discounted cash flows, using a discount rate determined by management to be commensurate with the risk inherent in our current business model.     In accordance with SFAS No. 142 goodwill and indefinite-lived intangible assets must be reviewed annually (or more frequently under certain conditions) for impairment in accordance with this Statement.  This impairment test uses a fair value approach.  We are annually required to complete Step 1 (determining and comparing the fair value of our reporting units to their carrying values, as of December 31, 2005, we had one reporting unit with goodwill) of the impairment test.  Step 2 is required to be completed if Step 1 indicates that the carrying value of the reporting unit exceeds the fair value, involves the calculation of the implied fair value of goodwill.  We completed Step 1 of the impairment assessment for the reporting unit with goodwill at its annual impairment testing date in 2005.  Based upon our valuation procedures, we determined that the fair value of the reporting unit exceeded its carrying value.  As such, we were not required to complete Step 2 of the impairment test and no impairment loss was recognized.   Prior to the fourth quarter of 2003, we had three reporting units with goodwill.  During the fourth quarter 2003, we evaluated our business opportunities and modified our strategies to focus on our core market offerings of ambulatory enteral feeding products and contract manufacturing services.  In conjunction with this refocus, we re-evaluated our reporting units and determined that the Therapeutics reporting unit, which had consisted of both our stationary and ambulatory enteral product lines, should be disaggregated such that the two product lines became separate reporting units because of the different market and sales practices of the stationary and ambulatory enteral product line.  In the fourth quarter of 2003, due to declining revenue and cash flows relating to the stationary enteral product line, we determined that indicators of impairment existed related to this reporting unit and again completed Step 1 of the impairment test.  Upon completion of Step 1, we determined that the fair value of the stationary enteral reporting unit was less than the carrying value including goodwill.  We completed Step 2 of the impairment assessment and a goodwill impairment loss has been recognized in 2003 for this reporting unit in the amount of $841,352.  This loss is included in “Asset and goodwill impairment” on the consolidated statement of operations.   Due to the significant changes to our overall business strategies, we also performed an analysis in the fourth quarter of 2003 to determine if any indicators of impairment existed related to the Applied Technology reporting unit.  We determined that our impairment test performed as part of our annual impairment analysis continued to be appropriate and no impairment loss was required.            In the fourth quarter of 2003 we also evaluated our long-lived assets to determine if indicators of impairment existed.  Based upon our assessment of cash flows related to our stationary enteral product line, we determined that impairment of the fixed asset value for our stationary enteral pumps existed.  We recorded an impairment charge of $725,615, as reflected in the 2003 consolidated statement of operations within “Asset and goodwill impairment.”   Net intangible assets and goodwill amounted to approximately $4.4 million as of December 31, 2005.  Net fixed assets amounted to approximately $4.6 million as of December 31, 2005.     Income Taxes   Income taxes are recorded based on the liability method, which requires recognition of deferred tax assets and liabilities based on differences between financial reporting and tax bases of assets and liabilities measured using enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.  A valuation allowance is recorded to reduce our deferred tax asset to an amount that is more likely than not to be realized, as determined based on our analyses of projected taxable income, including tax strategies available to generate future taxable income.  Our analyses of future taxable income are subject to a wide range of variables, many of which involve our estimates, and therefore our deferred tax asset may not be ultimately realized.  As of December 31, 2005 a full valuation has been recorded for all deferred tax assets.   New Accounting Pronouncements   In December 2004, the FASB issued Statement No. 123 (revised 2004), Share-Based Payment, which is a revision of FASB Statement No. 123, Accounting for Stock-Based Compensation. Statement 123(R) supersedes APB Opinion No. 25, Accounting for Stock Issued to Employees, and amends FASB Statement No. 95, Statement of Cash Flows. Generally, the approach in Statement 123(R) is similar to the approach described in Statement 123.  However, Statement 123(R) requires all share-based payments to employees, including grants of employee stock options, to be recognized in the income statement based on their fair values. Pro forma disclosure will no longer be an alternative.    Statement 123(R) must be adopted no later than January 1, 2006 and we expect to adopt Statement 123(R) on that date.  Statement 123(R) permits public companies to adopt its requirements using one of two methods, the “modified prospective” or the “modified retrospective.”  Management has determined that it will use the “modified prospective” method.  As permitted by Statement 123, the Company currently accounts for share-based payments to employees using Opinion 25’s intrinsic value method and, as such, generally recognizes no compensation cost for employee stock options.  Accordingly, the adoption of Statement 123(R)’s fair value method will have a significant impact on our result of operations, although it will have no impact on our overall financial position.  The impact of adoption of Statement 123(R) cannot be predicted at this time because it will depend on levels of share-based payments granted in the future.  However, had we adopted Statement 123(R) in prior periods, we believe that the impact of that standard would have approximated the impact of Statement 123 as described in the disclosure of pro forma net income and earnings per share in Note 1 to our consolidated financial statements.    In November 2004, the Financial Accounting Standards Board ("FASB") issued SFAS No. 151, "Inventory Costs," which clarifies the accounting for abnormal amounts of idle facility expense, freight, handling costs, and spoilage, requiring that such costs be recognized as current-period costs regardless of whether they meet the criterion of "so abnormal," currently required by the guidance in ARB No. 43, Chapter 4, "Inventory Pricing." SFAS No. 151 is effective for inventory costs incurred during fiscal years beginning after June 15, 2005, which for us is fiscal 2006. Because the provisions of this standard must be applied prospectively, there will be no effect on previously-issued financial statements.  It is not possible to predict the effect SFAS No. 151 might have on future reported results because it will depend on the levels of "abnormal" inventory costs incurred in the future, if any.             In May 2005, FASB issued Statement No. 154, “Accounting Changes and Error Corrections” (“SFAS 154”). SFAS 154 requires retrospective application to prior periods’ financial statements of changes in accounting principle.  It also requires that the new accounting principle be applied to the balances of assets and liabilities as of the beginning of the earliest period for which retrospective application is practicable and that a corresponding adjustment be made to the opening balance of retained earnings for that period rather than being reported in an income statement.  The statement will be effective for accounting changes and corrections of errors made in fiscal years beginning after December 15, 2005.  The Company does not expect the adoption of SFAS 154 to have a material effect on the Company’s consolidated financial position or results of operations.   We have reviewed all other recently issued accounting standards which have not yet been adopted in order to determine their potential effect, if any, on our results of operations or financial position.  Based on that review, we do not currently believe that any of these other recent accounting pronouncements will have a significant effect on its current or future financial position, results of operations, cash flows or disclosures.   Quarterly Financial Data   The following table sets forth a summary of our quarterly income statement data for the fiscal years ended December 31, 2005 and 2004.   Summary of Quarterly Data        12/05   9/05   6/05   3/05   12/04   9/04   6/04   3/04     Revenue   $ 9,354,882   $8,137,223   $6,797,653   $5,984,164   $ 5,862,248   $5,339,406   $6,223,997   $6,208,704     Gross profit   3,614,200   3,080,362   2,468,485   2,186,505   1,878,338   1,821,588   2,430,756   2,326,296     Net income (loss)      906,274     785,483     168,468     45,153     (285,929)     (294,721)     192,892     208,781     EPS basic   .26   .23   .05   .01   (.08)   (.09)   .06   .06     EPS diluted   .23   .22   .05   .01   (.08)   (.09)   .06   .06     ITEM 7A.           QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK   We are exposed to market risk in the form of fluctuations in interest rates and their potential impact upon our line of credit, currently with a zero balance and our industrial development bond of $1,200,000.  Principal payments of $100,000 are made annually on the industrial development bond, with the balance due October 1, 2016.  The variable rate on the line of credit is LIBOR plus 2.40%, which was 6.79% at December 31, 2005, and the variable rate on the industrial development bond is based on a weekly tax-exempt floater rate.  The line of credit matures annually in May.  At December 31, 2005, the above debt represented 64% of our total short-term funded debt and 61% of our total long-term funded debt compared with 65.3% short-term funded debt and 61.3% long-term funded debt at December 31, 2004.  For illustrative purposes only, the impact of market risk is estimated using a hypothetical increase in interest rates of one percentage point for both our variable rate debt and cash.  Based on hypothetical assumption, we would have incurred an additional $25,000 in interest expense and received $6,000 in additional interest income for the year ended December 31, 2005, we would have incurred an additional $22,000 in interest expense and received $6,000 in additional interest income for the year ended December 31, 2004, and an additional $35,000 in interest expense and received $4,000 in additional interest income for the year ended December 31, 2003.   We are also exposed to market risk in the form of fluctuations in interest rates and their potential impact on our fixed rate debt, which includes our term loan agreement, with a balance of $766,362 as of December 31, 2005, which is due on May 15, 2008 and is being amortized over a thirteen-year term at an interest rate of 5.4%.     Additionally, we held marketable equity securities with a fair value of $20,250 at December 31, 2005, consisting of stock of a public company in the small-cap market.  Gross unrealized losses on marketable equity securities were $0 for the year ended December 31, 2005.  Gross unrealized losses on marketable equity securities were $18,525 for the year ended December 31, 2004.  Gross unrealized gains on         marketable equity securities were $3,067 for the year ended December 31, 2003.
FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA     The following consolidated financial statements of ZEVEX are included beginning at page 46, immediately following Item 15:   Report of Independent Registered Public Accounting Firm Consolidated Balance Sheets as of December 31, 2005 and 2004 Consolidated Statements of Operations for the years ended December 31, 2005, 2004, and 2003 Consolidated Statements of Cash Flows for the years ended December 31, 2005, 2004, and 2003 Consolidated Statements of Stockholders’ Equity and Comprehensive Income for the years ended    December 31, 2005, 2004, and 2003 Notes to the Consolidated Financial Statements All schedules are omitted because they are not applicable or the required information is shown in the         financial statements or notes thereto.
CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE     None
CONTROLS AND PROCEDURES     Our management, including our CEO and CFO, has evaluated the effectiveness of our “disclosure controls and procedures” (the disclosure controls and other procedures that are designed to provide reasonable assurance that for recording, processing, summarizing, and reporting on a timely basis the information required to be disclosed in the periodic reports that we file with the U.S. Securities and Exchange Commission) as of the end of the fourth quarter.    The evaluation of our disclosure controls by the CEO and CFO included a review of the controls' objectives and design, the operation of the controls, and the effect of the controls on the information presented in this Annual Report.  Our management, including the CEO and CFO, does not expect that disclosure controls can or will prevent or detect all errors and all fraud, if any.  A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.  Also, projections of any evaluation of the disclosure controls and procedures to future periods are subject to the risk that the disclosure controls and procedures may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.   Based on their review and evaluation as of December 31, 2005, and subject to the inherent limitations as described above, our CEO and CFO have concluded that our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) are effective.  In addition, they are not aware of any change in our internal control over financial reporting during the quarter ended December 31, 2005 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
OTHER INFORMATION     None                      PART III
DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT     Portions of the registrant’s definitive Proxy Statement to be filed with the Securities and Exchange Commission within 120 days after registrant’s fiscal year end December 31, 2005 are incorporated by reference into Part III of this report.
EXECUTIVE COMPENSATION     The information required by this item will be set forth in the Proxy Statement and is incorporated in this report by reference.
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT     The information required by this item will be set forth in the Proxy Statement and is incorporated in this report by reference.
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS     The information required by this item will be set forth in the Proxy Statement and is incorporated in this report by reference.
PRINCIPAL ACCOUNTANT FEES AND SERVICES     During 2005 and 2004, Ernst & Young LLP examined the accounts of ZEVEX and its subsidiaries and also provided other audit services to us in connection with Securities and Exchange Commission filings.  A summary of these fees is set forth in the following table.   Fees Paid to Independent Auditors      Service provided   2005   2004     Audit fees   $144,654   $137,502     Audit-related fees   3,375   0     Tax fees   0   4,715     All other fees   0   0     In accordance with our Audit Committee Charter, the Audit Committee approves in advance any and all audit services, including audit engagement fees and terms, and non-audit services provided to us by our independent auditors (subject to the de minimus exception for non-audit services contained in Section 10A(i)(1)(B) of the Securities Exchange Act of 1934, as amended), all as required by applicable law or listing standards.  The independent auditors and our management are required to periodically report to the Audit Committee the extent of services provided by the independent auditors and the fees associated with these services.   In the Charter of the Audit Committee, as amended April 1, 2004, the Audit Committee has the sole authority to approve the audit and non-audit services of the auditors.  For 2005 and 2004, the Audit Committee has approved all audit and non-audit services by the auditors.                       PART IV   ITEM 15.  EXHIBITS, FINANCIAL STATEMENT SCHEDULES, AND REPORTS ON FORM 8-K   (a) Documents Filed as a Part of this Report.   (1) - Financial Statements.   The following consolidated balance sheets of ZEVEX International, Inc. as of December 31, 2005 and 2004, and the related consolidated statements of operations, stockholders' equity and comprehensive income and cash flows for each of the three years in the period ended December 31, 2004, are filed as part of this report:    Report of Ernst & Young LLP, Independent Registered Public Accounting Firm   Consolidated Balance Sheets   Consolidated Statements of Operations   Consolidated Statements of Cash Flows   Consolidated Statements of Stockholders' Equity and Comprehensive Income (loss)   Notes to Consolidated Financial Statements   (2) - Financial Statement Schedules   Not required in accordance with the applicable rules and regulations.   (3) - Exhibits   A list of exhibits required to be filed as part of this report is set forth in the Index to Exhibits, which immediately precedes such exhibits, and is incorporated herein by reference.          (b)   Reports on Form 8-K     None              SIGNATURES   Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.          ZEVEX INTERNATIONAL, INC.        Dated:  March 27, 2006   By: /s/ DAVID J. MCNALLY            David J. McNally            Chief Executive Officer             Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.    POWER OF ATTORNEY   Know all men by these presents, that each person whose signature appears below constitutes and appoints each of David J. McNally and Phillip L. McStotts, jointly and severally, his true and lawful attorney in fact and agent, with full power of substitution for him and in his name, place and stead, in any and all capacities to sign any or all amendments to this report on Form 10-K and to file the same, with all exhibits thereto and other documents in connection therewith with the Securities and Exchange Commission, hereby ratifying and confirming all that each said attorney in fact or his substitute or substitutes may do or cause to be done by virtue hereof.          Signature     Title     Date          /s/ JOHN T. LEMLEY   Chairman of the Board of Directors   March 27, 2006   John T. Lemley        /s/ DAVID J. MCNALLY      Chief Executive Officer,   March 27, 2006     David J. McNally   President (Principal Executive            Officer)                     /s/ PHILLIP L. MCSTOTTS   Director, Chief Financial Officer,   March 27, 2006     Phillip L. McStotts   Secretary, and Treasurer (Principal            Financial and Accounting Officer)                   /s/ BRADLY A. OLDROYD   Director   March 27, 2006   Bradly A. Oldroyd      /s/ DAVID B. KAYSEN   Director   March 27, 2006   David B. Kaysen        /s/ DAN M. ROBERTSON   Director   March 27, 2006   Dan M. Robertson      /s/ RICHARD L. SHANAMAN   Director   March 27, 2006   Richard L. Shanaman              INDEX TO EXHIBITS (Item 15(c))      Number   Exhibits        3.1   Articles of Incorporation of ZEVEX International, Inc., a Delaware corporation (1).     3.2   Bylaws of ZEVEX International, Inc., a Delaware corporation (1).                 10.1   Revolving Line of Credit Agreement between Bank One and ZEVEX International, Inc., dated September 29, 1997 (1).      10.5#   ZEVEX International, Inc., Amended 1993 Stock Option Plan (2).        10.6   Industrial Development Bond Offering Memorandum dated October 30, 1996 (3).        10.7   Industrial Development Bond Reimbursement Agreement, dated October 30, 1996 (3).        10.19#   ZEVEX International, Inc., 1999 Stock Option Plan and Form of Stock Option Grant (4).     10.20#   Form of Stock Option Grant to Messrs. McNally and McStotts (5).                 10.25   Amendment to Revolving Line of Credit Agreement between Bank One and ZEVEX International, Inc., dated June 29, 2001 (6).      10.27#   Executive Severance Package Agreement for Mr. McNally (7).        10.28#   Executive Severance Package Agreement for Mr. McStotts (7).        10.31   Amended and Restated Flocare 800 Manufacturing Agreement between ZEVEX   International, Inc. and Royal Numico, dated May 31, 2005 (9).    10.32   Amended and Restated Supply Agreement between ZEVEX International, Inc. and Royal         Numico, dated May 31, 2005 (9).         10.33   Amended and Restated Disposal Set Components Supply Agreement between  ZEVEX International, Inc. and Royal Numico, dated May 31, 2005 (9).      10.34                   Amended and Restated License Agreement between ZEVEX International, Inc. and Royal Numico, dated May 31, 2005 (9).      10.35   Amended and Restated License Agreement between ZEVEX International, Inc. and Royal    Numico, dated May 31, 2005 (9).    10.36   Maintenance and Service Agreement between ZEVEX International, Inc. and Royal   Numico, dated July 20, 2004 (8).    21   List of Subsidiaries.        23.1   Ernst & Young LLP consent         31.01   Certification of the Registrant’s Chief Executive Officer, as required by Section 302 of the Sarbanes-Oxley Act of 2002.          31.02   Certification of Registrant’s Chief Financial Officer, as required by Section 302 of the Sarbanes-Oxley Act of 2002.           32.01   Certification of Registrant’s Chief Executive Officer, as required by Section 906 of the Sarbanes-Oxley Act of 2002.           32.02   Certification of Registrant’s Chief Financial Officer, as required by Section 906 of the Sarbanes-Oxley Act of 2002.        (1)           Incorporated by reference to Amendment No. 1 on Registration Statement on Form S-1 filed October 24, 1997 (File No. 333-37189).    (2)           Incorporated by reference to Registration Statement on Form S-1 filed October 3, 1997 (File No. 001-12965).    (3)           Incorporated by reference to ZEVEX’s amended Quarterly Report on Form 10-Q for the quarter ended September 30, 1996 (File No. 033-19583).   (4)           Incorporated by reference to ZEVEX’s Annual Report on Form 10-K for the year ended December 31, 1998 (File No. 001-12965).   (5)           Incorporated by reference to ZEVEX’s Annual Report on Form 10-K for the year ended December 31, 1999 (File No. 001-12965).            (6)           Incorporated by reference to ZEVEX’s Annual Report on Form 10-K for the year ended December 31, 2001 (File No. 001-12965).    (7)           Incorporated by reference to ZEVEX’s Annual Report on Form 10-K for the year ended December 31, 2002 (File No. 001-12965).   (8)           Incorporated by reference to ZEVEX’s Annual Report on Form 10-K for the year ended December 31, 2002 (File No. 001-12965).   (9)           Incorporated by reference to ZEVEX’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2005 (File No. 001-12965).       #   Identifies a “management contract or compensatory plan or arrangement”.                   Exhibit 31.01 CERTIFICATION OF CHIEF EXECUTIVE OFFICER, AS REQUIRED BY SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002.   I, David J. McNally, certify that:   1. I have reviewed this annual report on Form 10-K of ZEVEX International, Inc.;   2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report;    3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report;    4. The registrant’s other certifying officer and I, are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:   a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;   b) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and   c) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and   5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):   a) All significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and   b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.   Dated:  March 27, 2006        By     /s/ David J. McNally              David J. McNally, CEO            (Chief Executive Officer)                            Exhibit 31.02 CERTIFICATION OF CHIEF FINANCIAL OFFICER, AS REQUIRED BY SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002.   I, Phillip L. McStotts, certify that:   1. I have reviewed this annual report on Form 10-K of ZEVEX International, Inc.;   2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report;    3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report;    4. The registrant’s other certifying officer and I, are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:   a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;   b) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and   c) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and   5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):   a) All significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and   b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.   Dated:  March 27, 2006         By     /s/ Phillip L. McStotts           Phillip L. McStotts, CFO            (Chief Financial Officer)                              EXHIBIT 32.01   CERTIFICATION OF CHIEF EXECUTIVE OFFICER, AS REQUIRED BY SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002.   I, David J. McNally, Chief Executive Officer  of ZEVEX International, Inc. hereby certify pursuant to 18 U.S.C. Section 1350 adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 that:    (i)           The accompanying annual report on Form 10-K for the fiscal year ended December 31, 2005, fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended; and    (ii)          The information contained in such report fairly presents, in all material respects, the financial condition and results of operations of ZEVEX International, Inc.   Dated:  March 27, 2006          By     /s/ David J. McNally              David J. McNally, CEO            (Chief Executive Officer)                           EXHIBIT 32.02   CERTIFICATION OF CHIEF FINANCIAL OFFICER, AS REQUIRED BY SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002.   I, Phillip L. McStotts, Chief Financial Officer of ZEVEX International, Inc. hereby certify pursuant to 18 U.S.C. Section 1350 adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 that:    (i)           The accompanying annual report on Form 10-K for the fiscal year ended December 31, 2005, fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended; and    (ii)          The information contained in such report fairly presents, in all material respects, the financial condition and results of operations of ZEVEX International, Inc.   Dated:  March 27, 2006           By     /s/ Phillip L. McStotts           Phillip L. McStotts, CFO            (Chief Financial Officer)                                CONSOLIDATED FINANCIAL STATEMENTS ZEVEX International, Inc. Years Ended December 31, 2005, 2004 and 2003 with Report of Independent Registered Public Accounting Firm                     ZEVEX International, Inc.   Consolidated Financial Statements   For the years ended December 31, 2005, 2004 and 2003     Contents      Report of Independent Registered Public Accounting Firm   48     Audited Consolidated Financial Statements      Consolidated Balance Sheets   49     Consolidated Statements of Operations   50     Consolidated Statements of Stockholders’ Equity and Comprehensive Income (loss)   51     Consolidated Statements of Cash Flows   52     Notes to Consolidated Financial Statements   53                  Report of Independent Registered Public Accounting Firm   Board of Directors and Stockholders ZEVEX International, Inc.   We have audited the accompanying consolidated balance sheets of ZEVEX International, Inc. as of December 31, 2005 and 2004 and the related consolidated statements of operations, stockholders’ equity and comprehensive income (loss), and cash flows for each of the three years in the period ended December 31, 2005. These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audits.   We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. We were not engaged to perform an audit of the Company’s internal control over financial reporting.  Our audit included consideration of internal controls over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting.  Accordingly, we express no such opinion.  An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.   In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of ZEVEX International, Inc. at December 31, 2005 and 2004, and the consolidated results of its operations and its cash flows for each of the three years in the period ended December 31, 2005, in conformity with U.S. generally accepted accounting principles.        Salt Lake City, Utah   /s/ Ernst & Young LLP   February 24, 2006                            ZEVEX INTERNATIONAL, INC.     CONSOLIDATED BALANCE SHEETS                                           December 31,       December 31,               ASSETS           2005       2004                               Current assets                         Cash and cash equivalents           $    1,284,218        $      212,859      Designated cash for sinking fund payment on industrial                         development bond           89,037        96,042      Accounts receivable, net of allowance for doubtful                         accounts of $130,000 in 2005 and $192,000 in 2004           5,641,229        3,563,436      Other receivable           -        35,500      Inventories           4,586,418        4,584,755      Marketable securities           20,250        29,250      Prepaid expenses and other current assets           193,362        149,690      Total current assets           11,814,514        8,671,532                                Property and equipment, net            4,639,136        4,345,942      Patents, trademarks and other intangibles, net           348,467        335,244      Goodwill, net           4,048,264        4,048,264      Total assets           $  20,850,381        $ 17,400,982                                LIABILITIES AND STOCKHOLDERS' EQUITY                                                   Current liabilities                         Accounts payable           $    2,462,071        $   1,949,618      Other accrued liabilities           1,290,911        606,734      Deferred revenue           52,081        -      Current portion of industrial development bond           100,000        100,000      Income taxes payable           2,965        2,005      Current portion of other long-term debt           56,219        53,246      Total current liabilities           3,964,247        2,711,603                                Industrial development bond           1,100,000        1,200,000      Other long-term debt           710,143        766,362                                Stockholders' equity                         Common stock; $.001 par value, 10,000,000                         authorized shares, 3,566,593 issued and 3,527,360                         outstanding at December 31, 2005 and  3,440,197                         issued and 3,400,964 outstanding at December 31, 2004           3,567        3,440      Additional paid in capital           16,719,396        16,290,452      Unrealized loss on marketable securities           -        (18,525)     Treasury stock, 39,233 shares (at cost) at                         December 31, 2005 and 2004           (89,422)       (89,422)     Accumulated deficit           (1,557,550)       (3,462,928)     Total stockholders' equity           15,075,991        12,723,017      Total liabilities and stockholders' equity           $  20,850,381        $ 17,400,982                                                    ZEVEX INTERNATIONAL, INC.         CONSOLIDATED STATEMENTS OF OPERATIONS                                                                                                 Year Ended December 31                     2005       2004       2003         Revenue:                                     Product sales            $ 29,721,595         $ 22,968,163         $ 24,015,057          Engineering services           552,327        666,192        1,854,819          Total revenue           30,273,922        23,634,355        25,869,876                                                Cost of sales           18,924,370        15,177,377        17,546,081          Gross profit           11,349,552        8,456,978        8,323,795                                                Operating expenses:                                     General and administrative           4,637,307        3,853,514        3,769,644          Selling and marketing           3,454,689        3,288,999        4,547,178          Research and development           1,208,466        1,430,692        1,817,581          Asset and goodwill impairment           -        -        1,566,967          Total operating expenses           9,300,462        8,573,205        11,701,370                                                Operating income (loss)            2,049,090        (116,227)       (3,377,575)                                               Other income (expense):                                     Interest and other income           12,234        22,209        8,406          Interest expense           (151,837)       (142,042)       (284,640)         Loss on sale of business           -        -        (4,692,445)         (Loss) gain on sale of assets/securities           (514)       25,861        -          Income (loss) before income taxes           1,908,973        (210,199)       (8,346,254)                                               (Provision) benefit for income taxes           (3,595)       31,222        68,712                                                Net income (loss)            $   1,905,378        $    (178,977)       $ (8,277,542)                                                                                     Basic net income (loss) per share           $            0.56        $          (0.05)       $          (2.43)                                               Weighted average shares outstanding           3,416,828        3,400,964        3,400,964                                                Diluted net income (loss) per share           $            0.52        $          (0.05)       $          (2.43)                                               Diluted weighted average shares outstanding           3,675,207        3,400,964        3,400,964                                                                                                                                 ZEVEX INTERNATIONAL, INC.                                                            CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY AND COMPREHENSIVE INCOME (LOSS)                                     Retained                                                     Earnings/       Unrealized (Loss) Gain                 Common Stock       Additional Paid-in       Treasury       (Accumulated       on Available-for-sale                 Shares   Amount       Capital       Stock       Deficit)       Securities       Total     Balances at January 1, 2003   3,440,197    $ 3,440        $       16,290,452        $ (89,422)       $  4,993,591        $                              -        $ 21,198,061      Comprehensive loss:                                                     Net loss   --   --       --       --       (8,277,542)       --       (8,277,542)     Other comprehensive income, net of tax:                                                     Change in unrealized gain on available-for-sale securities   --   --       --       --       --       3,067       3,067     Total comprehensive loss                                               (8,274,475)     Balances at December 31, 2003   3,440,197   3,440       16,290,452       (89,422)       (3,283,951)       3,067       12,923,586     Comprehensive loss:                                                     Net loss   --   --       --       --       (178,977)       --       (178,977)     Other comprehensive income, net of tax:                                                     Change in unrealized loss on available-for-sale securities   --   --       --       --       --       (21,592)       (21,592)     Total comprehensive loss                                               (200,569)     Balances at December 31, 2004   3,440,197   3,440       16,290,452       (89,422)       (3,462,928)       (18,525)       12,723,017     Comprehensive income:                                                     Net income   --   --       --       --       1,905,378       --       1,905,378     Other comprehensive income, net of tax:                                                     Change in unrealized loss on available-for-sale securities   --   --       --       --       --       18,525       18,525     Total comprehensive income                                               1,923,903     Exercise of stock options for cash   118,000   118       387,455       --       --       --       387,573     Issuance of stock for services   8,396   9       41,489       --       --       --       41,498     Balances at December 31, 2005   3,566,593    $ 3,567        $       16,719,396        $ (89,422)       $ (1,557,550)       $                              -        $ 15,075,991                      ZEVEX INTERNATIONAL, INC.       CONSOLIDATED STATEMENTS OF CASH FLOWS                                                   Year Ended December 31                 2005       2004       2003     Cash flows from operating activities                                 Net income (loss)           $ 1,905,378        $  (178,977)       $ (8,277,542)     Adjustments to reconcile net income (loss) to net cash                                 provided by operating activities                                  Depreciation and amortization           710,612        857,731        1,582,120      Asset and goodwill (and other than temporary) impairment           27,525        -        1,566,967      Loss on sale of business           -        -        4,692,445      Loss on disposal of asset           514        -        -      Stock issued for services           41,498        -        -      Provision for bad debts           13,696        6,521        (24,963)     Deferred income taxes           -        -        90,313      Realized gain on marketable securities           -        (3,361)       -      Changes in operating assets and liabilities, net of                                  acquisitions:                                 Designated cash for sinking fund payment                                 on industrial development bond           7,005        (765)       (1,492)     Accounts receivable           (2,091,489)       260,384        461,668      Inventories           (1,663)       (470,188)       2,234,289      Prepaid expenses and other assets           (8,172)       29,006        100,628      Accounts payable           512,453        408,918        (74,570)     Accrued and other liabilities           684,177        81,663        (95,694)     Deferred revenue           52,081        (426,067)       214,770      Income taxes receivable/payable           960        444,553        (159,026)                                       Net cash provided by operating activities           1,854,575        1,009,418        2,309,913                                        Cash flows from investing activities                                 Purchase of property and equipment           (977,316)       (379,886)       (610,685)     Additions of patents and trademarks           (40,227)       (29,634)       (94,150)     Proceeds from other receivable from sale of business           -        988,703        -      Redemption of available-for-sale marketable securities           -        40,519        -                                        Net cash (used in) provided by  investing activities           (1,017,543)       619,702        (704,835)                                       Cash flows from financing activities                                 Principal payments on capital lease and long-term debt           (53,246)       (173,380)       (908,989)     Payments on business and product line acquisition debt           -        -        (1,738,970)     Payment on industrial development bond           (100,000)       (100,000)       (100,000)     Net (payments on) proceeds from bank line of credit           -        (1,810,970)       1,810,970      Proceeds from exercise of stock options           387,573        -        -                                        Net cash provided by (used in) financing activities           234,327        (2,084,350)       (936,989)                                       Net increase (decrease) in cash and cash equivalents           1,071,359        (455,230)       668,089                                        Cash and cash equivalents at beginning of period           212,859        668,089        -                                        Cash and cash equivalents at end of period           $ 1,284,218        $   212,859        $     668,089                                                                        ZEVEX INTERNATIONAL, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS   1. Description of Organization and Business and Summary of Significant Accounting Policies   Description of Organization and Business   The Company was incorporated under the laws of the State of Nevada on December 30, 1987. The Company was originally incorporated as Downey Industries, Inc. and changed its name to ZEVEX International, Inc. on August 15, 1988. In November 1997, the Company reincorporated in Delaware.    The Company, through its divisions and subsidiary, engages in the business of designing, manufacturing, and distributing medical devices.  The Therapeutics division markets enteral nutrition delivery devices.  The Applied Technology division designs and manufactures advanced medical components and systems for other medical technology companies.  Until its sale on December 31, 2003, the Physical Evaluation division marketed industry-leading physical evaluation testing systems.     On December 31, 2003, the Company completed the sale of its Physical Evaluation business.  The transaction was accomplished by sale of all the issued and outstanding capital stock of JTech Medical Industries, Inc., (“JTech”), a wholly owned subsidiary of the Company.  The transaction was effected by a Stock Purchase Agreement (the “Stock Purchase Agreement”) dated December 31, 2003 by and between the Company and Mr. Leonard Smith, a former employee, officer and director of the Company (see Note 2).    Principles of Consolidation   The consolidated financial statements for 2005 include the accounts of ZEVEX International, Inc. (the Company) and its wholly owned operating subsidiary ZEVEX, Inc.  In 2003 the consolidated statements of operations also included the accounts of the Company’s wholly owned operating subsidiary, JTech.  As discussed above and in Note 2, JTech was sold effective December 31, 2003.  All significant intercompany balances and transactions have been eliminated in consolidation.     Use of Estimates   The preparation of financial statements in conformity with U.S. generally accepted accounting policies requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates and such differences could be material.   Revenue Recognition   The Company recognizes revenue from products sold directly to end customers when persuasive evidence of an arrangement exists, the price is fixed or determinable, shipment is made and title has passed, and collectibility is reasonably assured. If such criteria are not met, revenue is deferred.  As of December 31, 2005, 2004, and 2003, the Company had expensed as incurred shipping and handling costs, of $531,000, $490,000, and $437,000 respectively, which are included in selling and marketing.   We recognize revenue from products sold to distributors when persuasive evidence of an arrangement exists, the price is fixed or determinable, shipment is made and title has passed, and collectibility is reasonably assured.  If such criteria are not met, revenue is deferred.  There are no post-shipment obligations other than warranty service related to the product, no rights to return the product unless it is defective, no price protection, and no volume pricing rebates or stock rotation rights.            1. Description of Organization and Business and Summary of Significant Accounting Policies (continued)   Revenue Recognition (continued)   Contracts to perform engineering design and product development services are generally performed on a time and materials basis.  Revenue generally is recognized as milestones are achieved; costs are expensed as incurred.   Prior to the sale of the Physical Evaluation segment in 2003, the Company had limited software sales.  The Company accounted for revenue from software transactions pursuant to SOP No. 97-2, Software Revenue Recognition, as amended by SOP No. 98-4 and SOP No. 98-9.  SOP No. 97-2 requires that revenue recognized from software arrangements be allocated to each element of the arrangement based on the relative fair values of the elements, such as software products, upgrades, enhancements, post-contract customer support, installation, or training.  Under SOP No. 97-2, the determination of fair value is based on objective evidence, which is specific to the vendor.  If such evidence of fair value for each element of the arrangement does not exist, all revenue from the arrangement is deferred until such time that evidence of fair value does exist or until all elements of the arrangement are delivered.  As of December 31, 2003 the Company sold its Physical Evaluation business and no longer sells software and related services.   Cash and Cash Equivalents   The Company considers all certificates of deposit and highly liquid debt instruments with an insignificant interest rate risk and an original maturity of three months or less when purchased to be cash equivalents.   Concentrations of Credit Risk   The Company’s financial instruments consist primarily of cash and cash equivalents, marketable securities, trade accounts receivable and certain debt issuances (see Note 8). Cash and cash equivalents are held in federally insured financial institutions or invested in high-grade, short-term commercial paper issued by major United States corporations. Marketable securities consist principally of corporate stocks. The Company sells its products primarily to, and has trade receivables with, independent durable medical equipment manufacturers and dealers in the United States and abroad.  During 2005, two customers accounted for approximately 14% and 13% of revenue, respectively, and 43% of the accounts receivable balance at December 31, 2005. During 2004, one customer accounted for approximately 11% of revenue and 3% of the accounts receivable balance at December 31, 2004.  During 2003 no single customer accounted for over 10% of revenue.  Approximately 22% of product sales are to foreign customers in 2005, 13% in 2004, and 17% in 2003.   As a general policy, collateral is not required for accounts receivable; however, the Company periodically monitors the need for and records an allowance for doubtful accounts based upon expected collections of accounts receivable, historical bad debt rates, and specific identification of uncollectible accounts. Additionally, customers’ financial condition and creditworthiness are regularly evaluated. Historically losses on collection have not been material.   Inventories    Inventories are stated at the lower of cost or market; cost is determined using the first-in, first-out method.  The Company reviews inventory for indicators that its inventory exceeds its market value or that inventory quantities exceed amounts ultimately expected to be used or sold and writes down inventory as deemed necessary. As of December 31, 2005 and 2004, the Company had recorded an excess and obsolete reserve of approximately $284,000 and $270,000 respectively.              1. Description of Organization and Business and Summary of Significant Accounting Policies (continued) Sales Returns and Warranty   The Company records a provision for estimated sales returns and allowances and warranty reserve on products it has sold.  These estimates are based on historical sales returns and warranty expenses and other known factors.   Marketable Securities   As of December 31, 2005 and 2004, the Company’s marketable securities consisted of equity securities classified as available-for-sale.  Such securities are carried at their fair value based upon their quoted market prices at December 31, 2005 and 2004.     Unrealized gains and losses on available-for-sale securities are reported, net of tax, in a separate component of stockholders’ equity.    Realized gains and losses and declines in value, judged to be other-than-temporary on available-for-sale securities are included in interest and other income.  The cost of securities sold is based on the specific-identification method. Interest and dividends on securities classified as available-for-sale are included in other income.    In accordance with the provisions of Statement of Financial Accounting Standards (SFAS) No. 115, Accounting for Certain Investments in Debt and Equity Securities, Staff Accounting Bulletin No. 59, Accounting for Noncurrent Marketable Equity Securities, and EITF Issue No. 03-1, “The Meaning of Other-Than-Temporary Impairment and its Application to Certain Instruments”, in 2005, the Company recorded an other-than-temporary impairment loss on its available-for-sale securities of $27,525, which is reflected as a component of net income for the year ended December 31, 2005.  This writedown represents the amount of the unrealized loss as of the date of the writedown on the Company’s available-for-sale marketable securities that had previously been recorded in equity as part of other comprehensive income.   As of December 31, 2005, the Company did not have any unrealized holding gains or losses.  As of December 31, 2004, the Company had unrealized holding losses of $18,525 (see Note 4).      Property and Equipment   Property and equipment are stated at cost less accumulated depreciation.  If the Company determines that an impairment of its property and equipment exists, such property and equipment is written down to its fair value.  Depreciation is computed over expected useful lives of three to twenty-five years using the straight-line method.    Major replacements and refurbishment costs, which extend the useful lives of equipment, are capitalized and depreciated over the remaining useful life.  Normal maintenance and repairs are expensed as incurred.   Patents, Trademarks, and Other Intangibles   The costs of acquired and internally developed patents, trademarks, and other intangibles are amortized over the estimated seventeen year useful life of the intangible asset on a straight-line basis.  At December 31, 2005 and 2004, accumulated amortization related to patents, trademarks, and other intangibles was $170,063 and $143,059, respectively.  The Company periodically reviews the recoverability of its intangible assets and where impairment in value has occurred, such intangibles are written down to net realizable value.  During December 2003, the Company completed the sale of its Physical Evaluation business.  Upon completion of the sale, certain remaining JTech intangible assets and the related accumulated amortization were written-off.  The resulting loss of approximately $92,500 is included in the 2003 consolidated statement of operations within the loss on sale of business.            1. Description of Organization and Business and Summary of Significant Accounting Policies (continued)   Goodwill    As of December 31, 2005 and 2004, the Company’s gross goodwill balance was $4,568,577 with accumulated amortization of $520,313.   In accordance with SFAS No. 142 goodwill and indefinite-lived intangible assets must be reviewed annually (or more frequently under certain conditions) for impairment in accordance with this Statement.  This impairment test uses a fair value approach.  The Company is annually required to complete Step 1 (determining and comparing the fair value of the Company’s reporting units to their carrying values, as of December 31, 2005, the Company had one reporting unit with goodwill) of the impairment test.  Step 2 is required to be completed if Step 1 indicates that  the  carrying  value of  the  reporting  unit  exceeds  the  fair value and involves the  calculation  of  the implied fair  value of goodwill.  The Company completed Step 1 of the impairment assessment for its reporting unit with goodwill at its annual impairment testing date in 2005.   Based upon the Company’s valuation procedures, the Company determined that the fair value of the reporting unit exceeded its carrying value.  As such, the Company was not required to complete Step 2 of the impairment test and no impairment loss was recognized.   Prior to the fourth quarter of 2003, the Company had three reporting units with goodwill.  During the fourth quarter of 2003, the Company evaluated its business opportunities and modified its strategies to focus on its core market offerings of ambulatory enteral feeding and contract manufacturing services.  In conjunction with this refocus of the Company’s business, on December 31, 2003, the Company completed the sale of JTech, its Physical Evaluation business (see Note 2).  At the time of the sale, goodwill associated with JTech was stated at a net book value of $5,199,419 on the Company’s balance sheet. Upon completion of the sale, the goodwill and the related accumulated amortization were removed from the balance sheet and the resulting loss is included in the 2003 consolidated statement of operations within the “Loss on sale of business.”   The Company also re-valuated its reporting units and determined that the Therapeutics reporting unit, which had consisted of both the Company’s stationary and ambulatory enteral product lines, should be disaggregated such that the two product lines became separate reporting units for purposes of SFAS No. 142.  The Company made this determination because of the different market and sales practices of the stationary enteral product line as well as the change in the Company’s focus as described above.  Therefore, in the fourth quarter of 2003, due to declining sales and cash flows relating to this stationary enteral product line, the Company determined that indicators of impairment existed related to this reporting unit and again completed Step 1 of the impairment test.  Upon completion of Step 1, the Company determined that the fair value of the stationary enteral reporting unit was less than the carrying value including goodwill.  As such the Company completed Step 2 of the impairment assessment and a goodwill impairment loss of $841,352 was recorded in 2003 for this reporting unit.  This loss is included in “Asset and goodwill impairment” in the 2003 consolidated statement of operations.   Impairment of Long-Lived Assets   The Company assesses, on an ongoing basis, the recoverability of long-lived assets, comparing estimates of future undiscounted cash flows to net book value.  If future undiscounted cash flow estimates are less than net book value, net book value would be reduced to fair value based on estimates of discounted cash flows. The Company also evaluates amortization periods of assets, including intangible assets other than goodwill, to determine if events or circumstances warrant revised estimates of useful lives.    As noted above, the Company modified its future business strategies in the fourth quarter of 2003.  In conjunction with its business refocus, the Company evaluated its long-lived assets to determine if indicators of impairment existed.  Based upon an assessment of projected future cash flows related to its stationary             1. Description of Organization and Business and Summary of Significant Accounting Policies (continued) Impairment of Long-Lived Assets (continued)   enteral product line, the Company determined that impairment of the fixed asset value for its stationary enteral pumps existed.  The Company recorded an impairment charge of $725,615, as reflected in the 2003 consolidated statement of operations within “Asset and goodwill impairment.”    Income Taxes   The Company provides for income taxes based on the liability method, which requires recognition of deferred tax assets and liabilities based on the differences between financial reporting and tax bases of assets and liabilities measured using enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.  A valuation allowance has been established to reduce deferred tax assets to the amount that the Company believes will be more likely than not to be realized (see Note 7).    Stock Options   The Company has elected to follow the intrinsic value method under Accounting Principles Board Opinion (APB) No. 25, Accounting for Stock Issued to Employees, and related Interpretations (FIN No. 44) in accounting for its employee stock options rather than adopting the alternative fair value accounting provided for under SFAS No. 123, Accounting for Stock-Based Compensation.  During 2005, the Company recognized $33,688 in stock-based compensation for stock issued for the performance of services.  During 2004 and 2003, no stock-based compensation expense was recognized by the Company.    Had compensation expense for options under the Company’s two stock-based compensation plans been determined based on the fair value of the option at the grant dates for awards under those plans consistent with SFAS 123, the Company’s net income (loss) and earnings (loss) per share would have been adjusted to the pro forma amounts for the years ended December 31, as indicated below:          2005   2004   2003     Net income (loss) as reported   $  1,905,378   $   (178,977)   $  (8,277,542)     Less: Stock compensation expense determined under fair value method, net of related tax effects     1,114,901     599,040     334,800     Pro forma net income (loss)   $     790,477   $   (778,017)   $  (8,612,342)     Earnings (loss) per share:                 Basic – as reported   $             0.56   $          (0.05)   $            (2.43)     Basic – pro forma   $             0.23   $          (0.23)   $            (2.53)     Diluted – as reported   $             0.52   $          (0.05)   $            (2.43)     Diluted – pro forma   $             0.22   $          (0.23)   $            (2.53)     The fair value of the Company’s options was estimated at the date of grant using a Black-Scholes option pricing model with the following weighted-average assumptions for 2005, 2004, and 2003, respectively, for options where the stock price equals the exercise price: risk-free interest rate of 4.2%, 3.3%, and 3.0%; dividend yield of 0%; volatility factors of the expected market price of the Company’s common stock of .74, .73, and .77; and a weighted-average expected life of the option of 3.3, 3.5, and 3.5 years. The estimated weighted-average fair values of options granted in the years ended December 31, 2005, 2004, and 2003 were $2.49, $2.30, and $1.28, respectively.   The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions, including the expected stock price volatility. Because the Company’s employee stock options have characteristics different from those of traded options, and because             1. Description of Organization and Business and Summary of Significant Accounting Policies (continued)   Stock Options (continued)   changes in the subjective input assumptions can materially affect the fair value estimate, in management’s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.   For purposes of pro forma disclosures, the estimated fair value of the options is amortized on a straight-line basis over the options’ vesting period. Because the effect of SFAS No. 123 is prospective, the initial impact on pro forma net income (loss) may not be representative of compensation expense in future years.   Capitalized Software Development Costs for Internal Use   In accordance with the provisions of Statement of Position (SOP) No. 98-1, Accounting for the Costs of Software Developed or Obtained for Internal Use, the Company capitalizes internal and external costs to develop or obtain internal use software during the application development stage. Costs incurred during the preliminary project stage are expensed as incurred, as are training and maintenance costs.  Amortization is computed using the straight-line method over the estimated useful life of the assets, which has been determined to be three to five years.   Advertising Costs    Advertising costs are expensed as incurred. Advertising expenses were $69,759, $40,450, and $158,168, respectively, for the years ended December 31, 2005, 2004, and 2003.   Research and Development Costs   Research and Development costs are expensed as incurred.   New Accounting Pronouncements    In December 2004, the FASB issued Statement No. 123 (revised 2004), Share-Based Payment, which is a revision of FASB Statement No. 123, Accounting for Stock-Based Compensation. Statement 123(R) supersedes APB Opinion No. 25, Accounting for Stock Issued to Employees, and amends FASB Statement No. 95, Statement of Cash Flows. Generally, the approach in Statement 123(R) is similar to the approach described in Statement 123.  However, Statement 123(R) requires all share-based payments to employees, including grants of employee stock options, to be recognized in the income statement based on their fair values. Pro forma disclosure will no longer be an alternative.    Statement 123(R) must be adopted no later than January 1, 2006 and we expect to adopt Statement 123(R) on that date.  Statement 123(R) permits public companies to adopt its requirements using one of two methods, the “modified prospective” or the “modified retrospective.”  Management has determined that it will use the “modified prospective” method.  As permitted by Statement 123, the Company currently accounts for share-based payments to employees using Opinion 25’s intrinsic value method and, as such, generally recognizes no compensation cost for employee stock options.  Accordingly, the adoption of Statement 123(R)’s fair value method will have a significant impact on our result of operations, although it will have no impact on our overall financial position.  The impact of adoption of Statement 123(R) will depend on levels of share-based payments granted in the future.  Had we adopted Statement 123(R) in prior periods, we believe the impact of that standard would have approximated the impact of Statement 123 as described in the disclosure of pro forma net income and earnings per share in Note 1 to our consolidated financial statements.   Also, see note 10 for a discussion of the acceleration and vesting of certain of the stock options.            1. Description of Organization and Business and Summary of Significant Accounting Policies (continued) New Accounting Pronouncements (continued)   In November 2004, the Financial Accounting Standards Board ("FASB") issued SFAS No. 151, "Inventory Costs," which clarifies the accounting for abnormal amounts of idle facility expense, freight, handling costs, and spoilage, requiring that such costs be recognized as current-period costs regardless of whether they meet the criterion of "so abnormal," currently required by the guidance in ARB No. 43, Chapter 4, "Inventory Pricing." SFAS No. 151 is effective for inventory costs incurred during fiscal years beginning after June 15, 2005, which for the Company is fiscal 2006.  Because the provisions of this standard must be applied prospectively, there will be no effect on previously-issued financial statements.  It is not possible to predict the effect SFAS No. 151 might have on future reported results because it will depend on the levels of "abnormal" inventory costs incurred in the future, if any.  However, the Company has not historically had significant amounts of “abnormal” inventory costs, as defined by this Statement.   In May 2005, FASB issued Statement No. 154, “Accounting Changes and Error Corrections” (“SFAS 154”). SFAS 154 requires retrospective application to prior periods’ financial statements of changes in accounting principle.  It also requires that the new accounting principle be applied to the balances of assets and liabilities as of the beginning of the earliest period for which retrospective application is practicable and that a corresponding adjustment be made to the opening balance of retained earnings for that period rather than being reported in an income statement.  The statement will be effective for accounting changes and corrections of errors made in fiscal years beginning after December 15, 2005.  The Company does not expect the adoption of SFAS 154 to have a material effect on the Company’s consolidated financial position or results of operations.   We have reviewed all other recently issued accounting standards which have not yet been adopted in order to determine their potential effect, if any, on the results of operations or financial position of the Company. Based on that review, the Company does not currently believe that any of these other recent accounting pronouncements will have a significant effect on its current or future financial position, results of operations, cash flows or disclosures.   Net Income (Loss) Per Common Share   Basic net income (loss) per common share is calculated by dividing net income (loss) for the period by the weighted-average number of the Company’s common shares outstanding.   Diluted net income (loss) per common share includes the dilutive effect of options in the weighted-average number of the Company’s common shares outstanding, as calculated using the treasury stock method.   Net income (loss), as presented on the consolidated statements of operations, represents the numerator used in calculating basic and diluted net income (loss) per common share. The following table sets forth the computation of the shares used in determining basic and diluted net income (loss) per common share for the years ended December 31:      (in thousands)   2005   2004   2003     Denominator for basic net income (loss) per common share – weighted-average shares     3,417     3,401     3,401     Dilutive securities: options    258   –   –     Denominator for diluted net income (loss) per common share – adjusted weighted-average shares     3,675     3,401     3,401     Options to purchase approximately 114,500, 869,500, and 693,000 shares of common stock were outstanding at December 31, 2005, 2004, and 2003, respectively, but were not included in the computation of diluted earnings per share because they were anti-dilutive.            1. Description of Organization and Business and Summary of Significant Accounting Policies (continued)   Supplemental Cash Flow Information   Supplemental disclosures of cash flow information are as follows:                  Year Ended December 31         2005   2004   2003     Cash paid during the year for:                 Interest   $      150,457   $      141,589   $      323,802                       Schedule of non-cash  investing and financing activities:                 Unrealized gain (loss) on  available-for-sale marketable securities     –     (18,525)     3,067                       Acquisition of available-for-sale  marketable securities for accounts receivable      –     –     (84,933)      2. Acquisitions and Dispositions   During 2003, in response to the changing marketplaces of the Company’s business segments, the Company evaluated its business opportunities and the need to refocus the Company on its core technologies.  During this process, the Company examined and evaluated various options related to the divestiture of one or more business segments of the Company, partnering opportunities, and discontinuation of non-profitable product lines and business segments.  In the fourth quarter of 2003, it was determined that the Company would divest itself of the Physical Evaluation business due to its continued decline in sales, escalating sales and marketing expenses, additional research and development costs of the new product line, and the negative contribution margin of the business segment.  On December 31, 2003, the Company completed the sale of its Physical Evaluation business.  The transaction was accomplished through the sale of all the issued and outstanding capital stock of JTech, previously a wholly owned subsidiary of the Company.  The transaction was effected by a Stock Purchase Agreement dated December 31, 2003, by and between the Company and Mr. Leonard C. Smith, a former employee, officer and director of the Company, for a negotiated purchase price of $1.2 million, which was recorded as an “other receivable” at December 31, 2003.  Cash of $1,164,500 was received in 2004, and $35,500 was received in February 2005 when the Company satisfied certain obligations to JTech as set forth in the Stock Purchase Agreement.  Such obligations included the requirement to deliver inventory, upon completion of production, and certain other equipment.  The Company also had a manufacturing agreement for the manufacture of certain components and finished good products with JTech. Deferred revenue of $324,000 was recorded related to these obligations, all of which was realized in 2004. Additionally, pursuant to the Stock Purchase Agreement, the Company may receive additional payments from the purchaser based upon specifically identified JTech product sales in 2005.  During 2005 the Company recorded $33,181 of income under this agreement in interest and other income.   A loss on the sale of this business in the amount of $4,692,445 was recorded and is shown separately on the 2003 consolidated statement of operations.  Such loss consists of the write-off of goodwill and other intangibles as discussed in Note 1 as well as the write-off of certain other JTech related assets totaling approximately $242,000 and the accrual of legal costs associated with this transaction.                    3. Inventories   Inventories consist of the following at December 31:        2005   2004                   Materials   $3,139,027   $2,761,508     Work-in-progress   756,747   470,253     Finished goods, including completed subassemblies   690,644   1,352,994         $4,586,418   $4,584,755     4. Marketable Securities   The following is a summary of marketable securities at December 31, 2005:                  Gross Unrealized         Estimated Fair     Available-for-Sale   Cost       Gains       Value     Equity securities   $     20,250       $          --       $     20,250     As discussed in Note 1 above, an other-than-temporary impairment loss of $27,525 on available-for-sale marketable securities was recognized during 2005.    The following is a summary of marketable securities at December 31, 2004:                  Gross Unrealized         Estimated Fair     Available-for-Sale   Cost       Gains       Value     Equity securities   $     47,775       $   18,525       $     29,250     5. Property and Equipment   Property and equipment consist of the following at December 31:        2005   2004                   Machinery and equipment   $       596,227   $     1,155,635     Stationary enteral feeding pumps   3,858,699   4,233,699     Furniture and fixtures   1,191,617   1,829,402     Software   --   627,661     Tooling costs   1,514,827   1,859,194     Building   3,012,638   2,897,534     Land   1,084,415   1,084,415         11,258,423   13,687,540     Less accumulated depreciation and amortization   (6,619,287)   (9,341,598)         $    4,639,136   $     4,345,942     Stationary enteral feeding pumps represent acquired and self-constructed pumps that are placed with businesses and other users (at little or no cost to the users) under arrangements in which the pump users have an obligation to buy disposable products from the Company while they are using the pumps. To the extent that the users discontinue purchase of the disposables, the pumps are generally returned to the Company.  As discussed in Note 1 an impairment charge of $725,615 was recorded in 2003 related to stationary enteral feeding pumps.  This is included in the Therapeutics segment as described in Note 12.               5. Property and Equipment (continued)   Depreciation and amortization expense (including software amortization expense) for property and equipment for the years ended December 31, 2005, 2004, and 2003 amounted to $683,608, $833,064, and $1,546,110, respectively.  Assets that are fully depreciated including machinery and equipment, furniture and fixtures, tooling, and software, some of which are still in use by the Company, have been excluded from the table above.    6. Accrued Liabilities   Accrued liabilities consist of the following at December 31:          2005   2004                   Accrued payroll and related taxes and benefits   $888,656   $289,355     Accrued vacation   166,505   152,731     Warranty reserve   152,000   155,000     Other accrued expense    83,750   9,648         $1,290,911   $606,734       7. Income Taxes   Deferred tax assets and liabilities are classified as current or non-current, depending on the classification of the assets and liabilities to which they relate. Deferred taxes arising from temporary differences that are not related to an asset or liability are classified as current or non-current, depending on the periods in which the temporary differences are expected to reverse.   Significant components of the Company’s deferred income taxes as of December 31 are as follows:          2005   2004     Deferred tax assets:             Accruals and expenses not currently deductible   $        303,437   $        333,734     Fixed asset and other basis differences   120,230   183,659     Net operating loss carryforward    805,302   1,027,537     Federal and state tax credit carryforward   395,088   270,713     Charitable contribution carryforward   1,845,062   1,869,742     Capital loss carryforward   3,366,236   3,366,236     Total deferred tax assets   6,835,355   7,051,621                   Valuation allowance    (6,835,355)   (7,051,621)     Net deferred taxes   $                     -   $                     -     The Company has recorded a full valuation allowance against its deferred tax assets because the Company did not consider it more likely than not that these assets would be realized based upon limitations on usage of certain of the carryforwards as well as its cumulative net losses in recent years.  A portion of the valuation allowance related to the benefit for stock option exercise which increases the amount of the net operating loss carryforward.  When this benefit is used in the future the related reduction in the valuation allowance of $396,110 will be recorded to additional-paid-in-capital rather than income tax expense.                   7. Income Taxes (continued)   The (provision) benefit for income taxes consists of the following:          2005   2004   2003     Current taxes:                 Federal   $                 -   $       33,857   $     133,710     State   (3,595)   (2,635)   25,315     R&D credit   -   -   -     Deferred taxes:                 Federal   -   -   (82,323)     State   -   -   (7,990)     (Provision) benefit for income taxes   $       (3,595)   $       31,222   $       68,712     The actual tax benefit (expense) differs from the 34% federal statutory rate as follows:          2005   2004   2003                       Federal tax (expense) benefit at statutory rate   $   (649,051)   $       71,468   $  2,837,726     State income tax, (including state R & D credit), net   (15,188)   51,321   261,631     Research and development credit   74,682   89,998   103,108     Permanent basis differences   –   –   155,703                       Change in valuation allowance   612,376   (162,571)   (3,248,108)     Other non-deductible expenses   (26,414)   (18,994)   (41,348)     Total (provision) benefit for income taxes   $       (3,595)   $       31,222   $       68,712     The Company has federal net operating loss carryforwards totaling approximately $345,000 that begin to expire in 2023.  The Company has state net operating loss carryforwards totaling approximately $8,846,000 that begin to expire in 2016.  The Company has a federal and state charitable contribution carryforward totaling approximately $4,947,000 that is only recognizable if the Company has taxable income.  This carryforward expires in 2007.  Finally, the Company has federal capital loss carryforwards of approximately $9,901,000 that begin to expire in 2006.  Under the “change of ownership” provisions of the Internal Revenue Code, utilization of the Company’s net operating loss carryforward may be subject to an annual limitation.    8. Debt   Bank Line of Credit   The Company maintains a line of credit arrangement with a financial institution with availability of $3 million.  The line matures on May 29, 2006.  The Company expects that it will be able to renew its line of credit in May 2006.  The line of credit is collateralized by accounts receivable and inventory and bears interest at the rate of LIBOR plus 2.40%, which was an effective rate of 6.79% at December 31, 2005 and at prime rate of 5.25% at December 31, 2004. The Company’s balance on this line of credit was $0 at December 31, 2005 and 2004. Under the line of credit agreement, the Company is restricted from declaring cash dividends and must maintain certain levels of working capital and meet certain other financial covenants.  The Company was in compliance with such covenants as of December 31, 2005 and 2004.                8. Debt (continued)   Industrial Development Bond   On October 30, 1996, the Company completed a transaction defined as “Murray City, Utah, Adjustable Rate Industrial Development Revenue Bonds, Series 1997 (ZEVEX, Inc. Project)” in the amount of $2,000,000. The bonds are secured by an irrevocable Letter of Credit issued by a bank, which is subject to expiration no later than May 30, 2008. The bonds bear interest at an adjustable rate based on the weekly tax-exempt floater rate, as determined by the remarketing agent. The average rate for 2005 was 2.2%, the average rate for 2004 and 2003 was 1.3%.  The bonds mature on October 1, 2016. Principal reductions occur in the amount of $100,000 per year. The outstanding balance was $1,200,000 at December 31, 2005, of which $100,000 is classified as current.   Other Long-term Debt   On April 18, 2001, the Company entered into a Term Loan Agreement with a bank for the amount of $1,000,000.  The agreement, as amended, is secured by the Company’s manufacturing facility.  The note is due May 15, 2008 and is being amortized over a thirteen-year term, at an interest rate of 5.4%. The outstanding balance at December 31, 2005 was $766,362, of which $56,219 is classified as current.   The following is a summary of the Company’s debt and other long-term obligations:          Principal Payment due by period       Debt       Total     Less than 1 –year   More than 1- year   More than 2- year   More than 3- year   More than 4- year     More than 5- year     Industrial Development Bond        $1,200,000       $100,000       $100,000       $100,000       $100,000       $100,000       $700,000     Other  Long-term debt     766,362     56,219     59,358     650,785     -     -     -     Total   $1,966,362   $156,219   $159,358   $750,785   $100,000   $100,000   $700,000     9. Employee Benefit Plans   401(k) Profit Sharing Plan   The Company maintains a qualified 401(k) profit sharing plan covering substantially all employees. Eligible employees may defer a portion of their salary. At the discretion of the Board of Directors, the Company may make a contribution of up to four percent (4%) of the eligible employees’ salaries and an additional discretionary amount to be determined each year by the Board of Directors.  Employees are fully vested in the employer contributions after six years.  Contributions to the plan for the years ended December 31, 2005, 2004, and 2003 were $149,065, $128,202, and $146,590, respectively.    10. Stockholders’ Equity   Preferred Stock   The Company is authorized to issue 2,000,000 shares of $.001 par value preferred stock. None of the preferred stock was issued or outstanding at December 31, 2005 or 2004.   Common Stock Reserved for Future Issuance   At December 31, 2005, the Company had reserved 998,123 shares of common stock for future issuance under the Company’s stock option plans.            10. Stockholders’ Equity (continued)   Stock Option Plans   In September 1997, the Board of Directors consolidated its previous three stock option plans into one plan and established the Amended 1993 Stock Option Plan (the “1993 Plan”), which was ratified by shareholders in October 1993. Under the 1993 Plan, 600,000 shares of common stock were authorized for issuance, subject to adjustment for such matters as stock splits and stock dividends.   The 1993 Plan provides for the grant of incentive stock options, stock appreciation rights, and stock awards to eligible participants and may be administered by the Board of Directors or by the Compensation Committee.  All options granted under the 1993 Plan expire after five to seven years from the grant date and become exercisable no later than four years from the grant date.   During 1999, the Board of Directors established the 1999 Stock Option Plan (the “1999 Plan”), which was ratified by shareholders in June 1999. The 1999 Plan authorized 600,000 shares of common stock for issuance, subject to adjustment for such matters as stock splits and stock dividends.  The 1999 Plan provides for the grant of incentive stock options, stock appreciation rights, and stock awards to eligible participants and may be administered by the Board of Directors or by the Compensation Committee.  All options granted under the 1999 Plan expire after five to ten years from the grant date and become exercisable either immediately or up to six years from the grant date.   A summary of stock option activity for both plans, and related information for the years ended December 31, 2003, 2004, and 2005 follows:          Shares   Outstanding Stock Options       Weighted-         Available for Grant   Number of Shares       Price Per Share       Average Exercise Price                                   Balance at January 1, 2003   491,669   632,850       1.90-5.00       4.25     Options granted   (102,500)   102,500       1.90-2.86       1.99     Options exercised   –   –       –       –     Options canceled   42,400   (42,400)       4.00-5.00       4.85     Balance at December 31, 2003   431,569   692,950       1.90-5.00       3.86     Options granted   (444,000)   444,000       3.30-4.30       3.72     Options exercised   –   –       –       –     Options canceled   267,450   (267,450)       1.90-5.00       4.11     Balance at December 31, 2004   255,019   869,500       1.90-5.00       3.71     Options granted   (244,896)   244,896       3.60-12.83       8.19     Options exercised   –   (126,396)       1.90-4.75       3.31     Options canceled   20,000   (20,000)       2.97-4.05       3.95     Balance at December 31, 2005   30,123   968,000       $1.90-12.83       $4.89     Additionally, SFAS No. 123 requires that companies with wide ranges between the high and low exercise prices of its stock options segregate the exercise prices into ranges that are meaningful for assessing the timing and number of additional shares that may be issued and the cash that may be received as a result of the option exercises.                   Stock Option Plans (continued)   Below are the segregated ranges of exercise prices as of December 31, 2005:      Options Outstanding       Options Exercisable         Range of Exercise Prices             Number Outstanding       Weighted- Average Remaining Contractual Life         Weighted- Average Exercise Price             Number Exercisable         Weighted- Average Exercise Price     $1.90-3.63       460,000       4.6 years       $  3.29       449,250       $  3.28     3.94-5.00       393,500       4.3 years       4.46       254,500       4.62     12.83       114,500       5.8 years       12.83       50,000       12.83     $1.90-12.83       968,000       4.6 years       $  4.89       753,750       $  4.37     On December 14, 2005, the Company accelerated vesting of all unvested options to purchase shares of common stock that are held by current employees and directors that were unvested and granted prior to June 1, 2004, which have an exercise price per share ranging from $1.90 to $5.00.  Also, on December 14, 2005, the Company issued options to all independent directors to purchase shares of common stock that were immediately vested, which have an exercise price per share of $12.83.  Options to purchase approximately 353,375 shares of common stock were subject to this acceleration and the immediate vesting.  The exercise prices and number of shares subject to the accelerated options and the immediate vesting were unchanged.  The acceleration and the immediate vesting was effective December 14, 2005.  The acceleration and the immediate vesting of these options was undertaken to eliminate the future compensation expense of approximately $617,000 that the Company would have otherwise recognized under SFAS 123R in its future consolidated statements of operations.  By the accelerating and the immediate vesting of these options, the $617,000 is included in the pro-forma disclosure of stock-based compensation (Note 1).   11. Fair Value of Financial Instruments   The following methods and assumptions were used by the Company in estimating the fair value of its financial instruments:   Cash and cash equivalents, accounts receivable, and accounts payable: The carrying amounts reported in the balance sheet for cash and cash equivalents, accounts receivable, and accounts payable approximate their fair values.   Marketable securities: The Company determines fair values based on quoted market prices.   Bank line of credit, convertible debt, industrial development bond, other long-term debt and capital leases: The fair values of the Company’s bank line of credit and long-term debt and leases are estimated using discounted cash flow analyses, based on the Company’s current estimated incremental borrowing rates for similar types of borrowing arrangements.   The carrying amounts and fair values of the Company’s financial instruments are as follows at  December 31:        2005       2004         Carrying Amount       Fair Value       Carrying Amount       Fair Value     Cash and cash equivalents   $   1,284,218       $   1,284,218       $      212,859       $      212,859     Accounts receivable   5,641,229       5,641,229       3,563,436       3,563,436     Marketable securities   20,250       20,250       29,250       29,250     Accounts payable   2,462,071       2,462,071       1,949,618       1,949,618     Industrial development bond   1,200,000       1,200,000       1,300,000       1,300,000     Other long-term debt   766,362       749,066       819,608       822,997                12. Business Segments   The Company operates in two business segments: Therapeutics and Applied Technology.  The Therapeutics segment includes the manufacture and sale of feeding pumps and disposable sets used by patients who require direct gastrointestinal nutrition therapy (also called enteral feeding).  In the Applied Technology segment, the Company provides design and manufacturing services to medical device companies who, in turn, sell the Company’s components and systems under private labels or incorporate them into their products.  The Company evaluates the performance of the segments through gross profit, less selling and marketing expenses, and research and development expenses (or contribution margin).  The Company does not allocate general and administrative expenses by segment.  General and administrative expenses are included in Corporate and Unallocated amounts indicated below.     Segment information for the year ended December 31, 2005 (in thousands) is as follows:            Therapeutics     Applied Technology     Corporate and Unallocated       Total     Revenue   $        16,899   $        13,375   $              --   $    30,274     Cost of sales   10,911   8,013   --   18,924     Gross profit   5,988   5,362   --   11,350     Selling and marketing   2,829   626   --   3,455     Research and development   785   424   --   1,209     Contribution margin    2,374   4,312   --   6,686     General and administrative   --   --   4,637   4,637     Other (income)/expense   --   --   140   140     Provision for income taxes   --   --   4   4     Net income               $    1,905                           Total assets   $             135   $        4,048   $       16,667   $   20,850     Included in the segment assets disclosed above are specifically identified fixed assets and goodwill.  All assets other than those specifically identified fixed assets and goodwill are included in Corporate and Unallocated.  The only specifically identified fixed assets include nutritional pumps and tooling, which are included in the Therapeutics segment.  All other fixed assets are used jointly by the segments.  Goodwill represents approximately $4,048,000 in Applied Technology.   Segment information for the year ended December 31, 2004 (in thousands) is as follows:            Therapeutics     Applied Technology     Corporate and Unallocated       Total     Revenue   $        12,489   $        11,145   $              --   $    23,634     Cost of sales   8,159   7,018   --   15,177     Gross profit   4,330   4,127   --   8,457     Selling and marketing   2,937   352   --   3,289     Research and development   989   442   --   1,431     Contribution margin    404   3,333   --   3,737     General and administrative   --   --   3,853   3,853     Other (income)/expense   --   --   94   94     Benefit for income taxes   --   --   (31)   (31)     Net loss               $    (179)                           Total assets   $             364   $        4,048   $       12,989   $   17,401                    12. Business Segments (continued)   Through December 31, 2003 when such business was sold (see Note 2), the Company also operated in a third segment, the Physical Evaluation segment.  The Physical Evaluation segment includes the manufacture and sale of stand-alone and computerized products that measure isolated muscle strength, joint range of motion and sensation.       Segment information for the year ended December 31, 2003 (in thousands) is as follows:              Therapeutics     Physical Evaluation     Applied Technology   Corporate and Unallocated       Total     Revenue   $        12,406   $          3,016   $        10,448   $              --   $    25,870     Cost of sales   9,124   1,369   7,053   --   17,546     Gross profit   3,282   1,647   3,395   --   8,324     Selling and marketing   2,596   1,557   394   --   4,547     Research and development   760   763   295   --   1,818     Contribution margin    (74)   (673)   2,706   --   1,959     General and administrative   --   --   --   3,770   3,770     Asset and goodwill impairment   1,567   --   --   --   1,567     Loss on sale of business   --   4,692   --   --   4,692     Other (income)/expense   --   --   --   276   276     Benefit for income taxes   --   --   --   (68)   (68)     Net loss                   $ (8,278)                               Total assets   $             752   $             --   $        4,048   $       14,932   $   19,732       13. Related-Party Transactions   On December 31, 1998, the Company acquired JTech pursuant to a Stock Purchase Agreement among the Company and the four shareholders of JTech (the “JTech Stock Purchase”), including Leonard C. Smith. Mr. Smith was appointed to fill a vacancy on the Company’s Board of Directors, effective April 26, 1999 and served until December 2002.  Mr. Smith also served as Sr. Vice President of ZEVEX International, Inc. and of ZEVEX, Inc., until December 31, 2003.  On December 31, 2003, the Company completed the sale of its Physical Evaluation business to Mr. Smith (see Note 2).   During 2003, in response to the changing marketplaces of the Company’s business segments, the Company evaluated its business opportunities and the need to refocus the Company on its core technologies.  During this process, the Company examined and evaluated various options related to the divestiture of one or more business segments of the Company, partnering opportunities, and discontinuation of non-profitable product lines and business segments.  In the fourth quarter of 2003, it was determined that the Company would divest itself of the Physical Evaluation business due to its continued decline in sales, escalating sales and marketing expenses, additional research and development costs of the new product line, and the negative contribution margin of the business segment.  On December 31, 2003, the Company completed the sale of its Physical Evaluation business.  The transaction was accomplished through the sale of all the issued and outstanding capital stock of JTech, previously a wholly owned subsidiary of the Company.  The transaction was effected by a Stock Purchase Agreement dated December 31, 2003, by and between the Company and Mr. Leonard C. Smith, a former employee, officer and director of the Company, for a negotiated purchase price of $1.2 million, which was recorded as an “other receivable” at December 31, 2003.  Cash of $1,164,500 was received in 2004, and $35,500 was received in February 2005 when the Company satisfied certain obligations to JTech as set forth in the Stock Purchase Agreement.  Such obligations included the requirement  to  deliver  inventory,  upon  completion  of  production,  and  certain  other  equipment.    The           13. Related-Party Transactions (continued)   Company also had a manufacturing agreement for the manufacture of certain components and finished good products with JTech.  Deferred revenue of $324,000 was recorded related to these obligations, all of which was realized in 2004.  Additionally, pursuant to the Stock Purchase Agreement, the Company may receive additional payments from the purchaser based upon specifically identified JTech product sales in 2005.  During 2005 the Company earned $33,181 under this agreement.                                                  EXHIBIT 23.1       CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM   We consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-121591) pertaining to the ZEVEX International, Inc. 1999 Stock Option Plan and the ZEVEX International, Inc. Amended 1993 Stock Option Plan of ZEVEX International, Inc., of our report dated February 24, 2006, with respect to the consolidated financial statements of ZEVEX International, Inc., included in this Annual Report (Form 10-K) for the year ended December 31, 2005.       Salt Lake City, Utah    March 21, 2006     /s/ Ernst & Young LLP                   -----END PRIVACY-ENHANCED MESSAGE-----
-- 40                  SIGNATURES   -- 39               PART I